EP2297332A2 - Verfahren und plattformen zur arzneistoffentdeckung - Google Patents
Verfahren und plattformen zur arzneistoffentdeckungInfo
- Publication number
- EP2297332A2 EP2297332A2 EP09763772A EP09763772A EP2297332A2 EP 2297332 A2 EP2297332 A2 EP 2297332A2 EP 09763772 A EP09763772 A EP 09763772A EP 09763772 A EP09763772 A EP 09763772A EP 2297332 A2 EP2297332 A2 EP 2297332A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- human
- pluripotent stem
- differentiated
- induced pluripotent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 178
- 238000007876 drug discovery Methods 0.000 title description 15
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims abstract description 255
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 131
- 230000036541 health Effects 0.000 claims abstract description 125
- 230000001413 cellular effect Effects 0.000 claims abstract description 67
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 67
- 201000010099 disease Diseases 0.000 claims abstract description 63
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 15
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims abstract description 4
- 206010070863 Toxicity to various agents Diseases 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 534
- 108700028369 Alleles Proteins 0.000 claims description 103
- 230000014509 gene expression Effects 0.000 claims description 90
- 239000003814 drug Substances 0.000 claims description 80
- 210000000130 stem cell Anatomy 0.000 claims description 70
- 102000004169 proteins and genes Human genes 0.000 claims description 55
- 229940079593 drug Drugs 0.000 claims description 53
- 238000003556 assay Methods 0.000 claims description 37
- 210000003494 hepatocyte Anatomy 0.000 claims description 36
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 31
- 210000005260 human cell Anatomy 0.000 claims description 31
- 210000002569 neuron Anatomy 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 29
- 102000005962 receptors Human genes 0.000 claims description 28
- 108020003175 receptors Proteins 0.000 claims description 28
- 210000001178 neural stem cell Anatomy 0.000 claims description 25
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 24
- 210000003897 hepatic stem cell Anatomy 0.000 claims description 21
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 20
- 208000012902 Nervous system disease Diseases 0.000 claims description 20
- 230000035945 sensitivity Effects 0.000 claims description 20
- 208000019022 Mood disease Diseases 0.000 claims description 19
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 19
- 208000030159 metabolic disease Diseases 0.000 claims description 16
- 230000000747 cardiac effect Effects 0.000 claims description 13
- 238000003205 genotyping method Methods 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 230000001988 toxicity Effects 0.000 claims description 13
- 231100000419 toxicity Toxicity 0.000 claims description 13
- 208000026278 immune system disease Diseases 0.000 claims description 12
- 208000030533 eye disease Diseases 0.000 claims description 11
- 208000014951 hematologic disease Diseases 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 11
- 208000023504 respiratory system disease Diseases 0.000 claims description 11
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 9
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims description 9
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 229910052791 calcium Inorganic materials 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 9
- 239000013642 negative control Substances 0.000 claims description 9
- 102000001253 Protein Kinase Human genes 0.000 claims description 8
- 230000002438 mitochondrial effect Effects 0.000 claims description 8
- 108060006633 protein kinase Proteins 0.000 claims description 8
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- 108010029485 Protein Isoforms Proteins 0.000 claims description 7
- 102000001708 Protein Isoforms Human genes 0.000 claims description 7
- 230000006907 apoptotic process Effects 0.000 claims description 7
- 230000003834 intracellular effect Effects 0.000 claims description 7
- 210000004498 neuroglial cell Anatomy 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 230000004845 protein aggregation Effects 0.000 claims description 5
- 230000032258 transport Effects 0.000 claims description 5
- 102000004310 Ion Channels Human genes 0.000 claims description 4
- 230000002518 glial effect Effects 0.000 claims description 4
- 239000002831 pharmacologic agent Substances 0.000 claims description 4
- 230000003185 calcium uptake Effects 0.000 claims description 3
- 230000035992 intercellular communication Effects 0.000 claims description 3
- 230000004899 motility Effects 0.000 claims description 3
- 210000005265 lung cell Anatomy 0.000 claims 3
- 238000012163 sequencing technique Methods 0.000 claims 2
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 claims 1
- 108090000365 Cytochrome-c oxidases Proteins 0.000 claims 1
- 210000002064 heart cell Anatomy 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
- 241000700605 Viruses Species 0.000 description 136
- 102000004196 processed proteins & peptides Human genes 0.000 description 103
- 108090000765 processed proteins & peptides Proteins 0.000 description 103
- 229920001184 polypeptide Polymers 0.000 description 102
- 150000001875 compounds Chemical class 0.000 description 58
- 239000002609 medium Substances 0.000 description 57
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 53
- 239000000523 sample Substances 0.000 description 50
- 101150086694 SLC22A3 gene Proteins 0.000 description 46
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 44
- 238000012258 culturing Methods 0.000 description 41
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 38
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 38
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 37
- 230000006698 induction Effects 0.000 description 33
- 238000012360 testing method Methods 0.000 description 32
- 210000001519 tissue Anatomy 0.000 description 32
- 150000007523 nucleic acids Chemical class 0.000 description 28
- 210000002161 motor neuron Anatomy 0.000 description 27
- 108020004707 nucleic acids Proteins 0.000 description 27
- 102000039446 nucleic acids Human genes 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 26
- 208000002320 spinal muscular atrophy Diseases 0.000 description 26
- 241001430294 unidentified retrovirus Species 0.000 description 25
- 230000003612 virological effect Effects 0.000 description 25
- 210000002966 serum Anatomy 0.000 description 23
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 22
- 229940124597 therapeutic agent Drugs 0.000 description 22
- -1 by a biopsy Substances 0.000 description 21
- 238000009396 hybridization Methods 0.000 description 21
- 208000018737 Parkinson disease Diseases 0.000 description 20
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 20
- 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 description 18
- 102100021947 Survival motor neuron protein Human genes 0.000 description 18
- 239000003596 drug target Substances 0.000 description 18
- 239000012091 fetal bovine serum Substances 0.000 description 18
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 18
- 238000004806 packaging method and process Methods 0.000 description 18
- 230000001177 retroviral effect Effects 0.000 description 18
- 230000003321 amplification Effects 0.000 description 17
- 238000003199 nucleic acid amplification method Methods 0.000 description 17
- 210000002950 fibroblast Anatomy 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 238000010361 transduction Methods 0.000 description 16
- 230000026683 transduction Effects 0.000 description 16
- 210000002242 embryoid body Anatomy 0.000 description 15
- 230000004044 response Effects 0.000 description 14
- 241000701161 unidentified adenovirus Species 0.000 description 14
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 13
- 210000005064 dopaminergic neuron Anatomy 0.000 description 13
- 239000013604 expression vector Substances 0.000 description 13
- 239000001963 growth medium Substances 0.000 description 13
- 229940000406 drug candidate Drugs 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 11
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 11
- 239000000090 biomarker Substances 0.000 description 11
- 150000002611 lead compounds Chemical class 0.000 description 11
- 210000003205 muscle Anatomy 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- 210000001082 somatic cell Anatomy 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 238000004113 cell culture Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000001574 biopsy Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000001939 inductive effect Effects 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 8
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 206010043276 Teratoma Diseases 0.000 description 8
- 210000000577 adipose tissue Anatomy 0.000 description 8
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- 210000001671 embryonic stem cell Anatomy 0.000 description 8
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 8
- 230000000877 morphologic effect Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 229930002330 retinoic acid Natural products 0.000 description 8
- 239000012679 serum free medium Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 108010023082 activin A Proteins 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 238000007877 drug screening Methods 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 210000004248 oligodendroglia Anatomy 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 229960001727 tretinoin Drugs 0.000 description 7
- JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 102000003964 Histone deacetylase Human genes 0.000 description 6
- 108090000353 Histone deacetylase Proteins 0.000 description 6
- 206010061598 Immunodeficiency Diseases 0.000 description 6
- 241000713666 Lentivirus Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 108010082820 apicidin Proteins 0.000 description 6
- 229930186608 apicidin Natural products 0.000 description 6
- 239000006143 cell culture medium Substances 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000010195 expression analysis Methods 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 210000005087 mononuclear cell Anatomy 0.000 description 6
- 210000002894 multi-fate stem cell Anatomy 0.000 description 6
- 238000003499 nucleic acid array Methods 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000012096 transfection reagent Substances 0.000 description 6
- 102100024810 DNA (cytosine-5)-methyltransferase 3B Human genes 0.000 description 5
- 101710123222 DNA (cytosine-5)-methyltransferase 3B Proteins 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 108010025020 Nerve Growth Factor Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 238000000423 cell based assay Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 238000002493 microarray Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000007423 screening assay Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241000713800 Feline immunodeficiency virus Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 description 4
- 101000976622 Homo sapiens Zinc finger protein 42 homolog Proteins 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 102100039064 Interleukin-3 Human genes 0.000 description 4
- 108010002386 Interleukin-3 Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 101000976618 Mus musculus Zinc finger protein 42 Proteins 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 102000012211 Retinoic Acid 4-Hydroxylase Human genes 0.000 description 4
- 108010022037 Retinoic Acid 4-Hydroxylase Proteins 0.000 description 4
- 241000713311 Simian immunodeficiency virus Species 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 101710192266 Tegument protein VP22 Proteins 0.000 description 4
- 101001029301 Xenopus tropicalis Forkhead box protein D3 Proteins 0.000 description 4
- 102100023550 Zinc finger protein 42 homolog Human genes 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 210000001130 astrocyte Anatomy 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000001973 epigenetic effect Effects 0.000 description 4
- 210000004700 fetal blood Anatomy 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 238000003365 immunocytochemistry Methods 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 230000011987 methylation Effects 0.000 description 4
- 238000007069 methylation reaction Methods 0.000 description 4
- 210000000963 osteoblast Anatomy 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 230000004043 responsiveness Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 3
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 3
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 3
- 102100026882 Alpha-synuclein Human genes 0.000 description 3
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 3
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 3
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 3
- 101000941879 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 2 Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 108090000862 Ion Channels Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 101710128836 Large T antigen Proteins 0.000 description 3
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 description 3
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 3
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 3
- 241000714177 Murine leukemia virus Species 0.000 description 3
- 102000007072 Nerve Growth Factors Human genes 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 108090000185 alpha-Synuclein Proteins 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000001857 anti-mycotic effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000002543 antimycotic Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229930189065 blasticidin Natural products 0.000 description 3
- 230000003139 buffering effect Effects 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 239000002771 cell marker Substances 0.000 description 3
- 230000010307 cell transformation Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000001143 conditioned effect Effects 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000003291 dopaminomimetic effect Effects 0.000 description 3
- 238000009509 drug development Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 102000045246 noggin Human genes 0.000 description 3
- 108700007229 noggin Proteins 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 102000045222 parkin Human genes 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- 230000007502 viral entry Effects 0.000 description 3
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 2
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
- 208000019581 Abnormal cellular phenotype Diseases 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- FMGYKKMPNATWHP-UHFFFAOYSA-N Cyperquat Chemical compound C1=C[N+](C)=CC=C1C1=CC=CC=C1 FMGYKKMPNATWHP-UHFFFAOYSA-N 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 102100036912 Desmin Human genes 0.000 description 2
- 108010044052 Desmin Proteins 0.000 description 2
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 2
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 description 2
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 2
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 2
- 208000008852 Hyperoxaluria Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 102100020880 Kit ligand Human genes 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000008955 Mucolipidoses Diseases 0.000 description 2
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000012580 N-2 Supplement Substances 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 2
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101710149951 Protein Tat Proteins 0.000 description 2
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 101150015954 SMN2 gene Proteins 0.000 description 2
- 102100038081 Signal transducer CD24 Human genes 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- IYOZTVGMEWJPKR-IJLUTSLNSA-N Y-27632 Chemical compound C1C[C@@H]([C@H](N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-IJLUTSLNSA-N 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000005735 apoptotic response Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000002790 cross-validation Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 210000005045 desmin Anatomy 0.000 description 2
- 108010007093 dispase Proteins 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000010201 enrichment analysis Methods 0.000 description 2
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 2
- 229960002435 fasudil Drugs 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000011223 gene expression profiling Methods 0.000 description 2
- 210000001654 germ layer Anatomy 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 2
- 229940097277 hygromycin b Drugs 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 238000011560 inbred animal model Methods 0.000 description 2
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000004065 mitochondrial dysfunction Effects 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- VBJZDMOTYJEHEP-UHFFFAOYSA-N n,n'-dihydroxynonanediamide Chemical compound ONC(=O)CCCCCCCC(=O)NO VBJZDMOTYJEHEP-UHFFFAOYSA-N 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 230000009207 neuronal maturation Effects 0.000 description 2
- FSVCQIDHPKZJSO-UHFFFAOYSA-L nitro blue tetrazolium dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- FYBHCRQFSFYWPY-UHFFFAOYSA-N purmorphamine Chemical compound C1CCCCC1N1C2=NC(OC=3C4=CC=CC=C4C=CC=3)=NC(NC=3C=CC(=CC=3)N3CCOCC3)=C2N=C1 FYBHCRQFSFYWPY-UHFFFAOYSA-N 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 102000000568 rho-Associated Kinases Human genes 0.000 description 2
- 108010041788 rho-Associated Kinases Proteins 0.000 description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000002363 skeletal muscle cell Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229940043263 traditional drug Drugs 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- 229960000237 vorinostat Drugs 0.000 description 2
- RAVVEEJGALCVIN-AGVBWZICSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RAVVEEJGALCVIN-AGVBWZICSA-N 0.000 description 1
- ZVEMACCDKBQNGX-KALODSIISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;butanoic acid Chemical compound CCCC(O)=O.CCCC(O)=O.CCCC(O)=O.CCCC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N.OC(=O)[C@@H](N)CCCN=C(N)N.OC(=O)[C@@H](N)CCCN=C(N)N ZVEMACCDKBQNGX-KALODSIISA-N 0.000 description 1
- GNYCTMYOHGBSBI-SVZOTFJBSA-N (3s,6r,9s,12r)-6,9-dimethyl-3-[6-[(2s)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone Chemical compound C([C@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H](C(N[C@H](C)C(=O)N1)=O)C)CCCCC(=O)[C@@H]1CO1 GNYCTMYOHGBSBI-SVZOTFJBSA-N 0.000 description 1
- SGYJGGKDGBXCNY-QXUYBEEESA-N (3s,9s,12r)-3-benzyl-6,6-dimethyl-9-[6-[(2s)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone Chemical compound C([C@H]1C(=O)NC(C(N[C@@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@@H]2C(=O)N1)=O)(C)C)CCCCC(=O)[C@@H]1CO1 SGYJGGKDGBXCNY-QXUYBEEESA-N 0.000 description 1
- WXKIMKVDAGLLKH-DMSVGWIRSA-N (4s)-2-tert-butyl-5-[[(2s)-1-[[(2s)-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-[[(2s,3s)-3-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C(O)=O)C(C)(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)OCC1=CC=CC=C1 WXKIMKVDAGLLKH-DMSVGWIRSA-N 0.000 description 1
- JVJFIQYAHPMBBX-FNORWQNLSA-N (E)-4-hydroxynon-2-enal Chemical compound CCCCCC(O)\C=C\C=O JVJFIQYAHPMBBX-FNORWQNLSA-N 0.000 description 1
- QRPSQQUYPMFERG-LFYBBSHMSA-N (e)-5-[3-(benzenesulfonamido)phenyl]-n-hydroxypent-2-en-4-ynamide Chemical compound ONC(=O)\C=C\C#CC1=CC=CC(NS(=O)(=O)C=2C=CC=CC=2)=C1 QRPSQQUYPMFERG-LFYBBSHMSA-N 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- ZIIQCSMRQKCOCT-UHFFFAOYSA-N 2-acetamido-3-methyl-3-nitrososulfanylbutanoic acid Chemical compound CC(=O)NC(C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- PTYVBEKOPJHZLJ-UHFFFAOYSA-N 2-nitropropanoic acid Chemical compound OC(=O)C(C)[N+]([O-])=O PTYVBEKOPJHZLJ-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- DHXNZYCXMFBMHE-UHFFFAOYSA-M 3-bromopropanoate Chemical compound [O-]C(=O)CCBr DHXNZYCXMFBMHE-UHFFFAOYSA-M 0.000 description 1
- WBLZUCOIBUDNBV-UHFFFAOYSA-N 3-nitropropanoic acid Chemical compound OC(=O)CC[N+]([O-])=O WBLZUCOIBUDNBV-UHFFFAOYSA-N 0.000 description 1
- IDDDVXIUIXWAGJ-DDSAHXNVSA-N 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-DDSAHXNVSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 208000011403 Alexander disease Diseases 0.000 description 1
- 241001136792 Alle Species 0.000 description 1
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 229930182536 Antimycin Natural products 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 201000005943 Barth syndrome Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 241000714266 Bovine leukemia virus Species 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- 102000004274 CCR5 Receptors Human genes 0.000 description 1
- 108010017088 CCR5 Receptors Proteins 0.000 description 1
- 108010061299 CXCR4 Receptors Proteins 0.000 description 1
- 102000012000 CXCR4 Receptors Human genes 0.000 description 1
- 101100190541 Caenorhabditis elegans pink-1 gene Proteins 0.000 description 1
- 101100257133 Caenorhabditis elegans sma-3 gene Proteins 0.000 description 1
- 208000022526 Canavan disease Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010050215 Carnitine palmitoyltransferase deficiency Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- SGYJGGKDGBXCNY-UHFFFAOYSA-N Chlamydocin Natural products N1C(=O)C2CCCN2C(=O)C(CC=2C=CC=CC=2)NC(=O)C(C)(C)NC(=O)C1CCCCCC(=O)C1CO1 SGYJGGKDGBXCNY-UHFFFAOYSA-N 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 244000175448 Citrus madurensis Species 0.000 description 1
- 235000004332 Citrus madurensis Nutrition 0.000 description 1
- 235000007438 Citrus mitis Nutrition 0.000 description 1
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 description 1
- 208000010200 Cockayne syndrome Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 241001136239 Cymbidium hybrid cultivar Species 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 102100022334 Dihydropyrimidine dehydrogenase [NADP(+)] Human genes 0.000 description 1
- 108010066455 Dihydrouracil Dehydrogenase (NADP) Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010049020 Encephalitis periaxialis diffusa Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 208000001948 Farber Lipogranulomatosis Diseases 0.000 description 1
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 1
- 102000003969 Fibroblast growth factor 4 Human genes 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102100037060 Forkhead box protein D3 Human genes 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 208000025499 G6PD deficiency Diseases 0.000 description 1
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 description 1
- 208000009796 Gangliosidoses Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- 206010018444 Glucose-6-phosphate dehydrogenase deficiency Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102100033495 Glycine dehydrogenase (decarboxylating), mitochondrial Human genes 0.000 description 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 1
- 206010018464 Glycogen storage disease type I Diseases 0.000 description 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 108010051041 HC toxin Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101001029308 Homo sapiens Forkhead box protein D3 Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 description 1
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 1
- 101100510266 Homo sapiens KLF4 gene Proteins 0.000 description 1
- 101100137155 Homo sapiens POU5F1 gene Proteins 0.000 description 1
- 101000741544 Homo sapiens Properdin Proteins 0.000 description 1
- 101000835739 Homo sapiens Putative teratocarcinoma-derived growth factor 3 Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 101000784538 Homo sapiens Zinc finger and SCAN domain-containing protein 10 Proteins 0.000 description 1
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 description 1
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 1
- 102100024390 Insulin gene enhancer protein ISL-2 Human genes 0.000 description 1
- 101710156777 Insulin gene enhancer protein ISL-2 Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- 208000027747 Kennedy disease Diseases 0.000 description 1
- 101710177504 Kit ligand Proteins 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- DAQAKHDKYAWHCG-UHFFFAOYSA-N Lactacystin Natural products CC(=O)NC(C(O)=O)CSC(=O)C1(C(O)C(C)C)NC(=O)C(C)C1O DAQAKHDKYAWHCG-UHFFFAOYSA-N 0.000 description 1
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 208000010557 Lipid storage disease Diseases 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000713821 Mason-Pfizer monkey virus Species 0.000 description 1
- 206010068836 Metabolic myopathy Diseases 0.000 description 1
- 206010059521 Methylmalonic aciduria Diseases 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
- 208000003430 Mitral Valve Prolapse Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 1
- 102000004855 Multi drug resistance-associated proteins Human genes 0.000 description 1
- 108090001099 Multi drug resistance-associated proteins Proteins 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- IDQPVOFTURLJPT-UHFFFAOYSA-N N,N'-dihydroxyoctanediamide Chemical compound ONC(=O)CCCCCCC(=O)NO IDQPVOFTURLJPT-UHFFFAOYSA-N 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 101710202061 N-acetyltransferase Proteins 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methyl-N-phenylamine Natural products CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 206010052057 Neuroborreliosis Diseases 0.000 description 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 1
- 208000035544 Nonketotic hyperglycinaemia Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 241000337007 Oceania Species 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 206010069350 Osmotic demyelination syndrome Diseases 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010049226 Oxalosis Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 241000364051 Pima Species 0.000 description 1
- 102100039277 Pleiotrophin Human genes 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102100026407 Putative teratocarcinoma-derived growth factor 3 Human genes 0.000 description 1
- 208000030555 Pygmy Diseases 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 208000005587 Refsum Disease Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000712909 Reticuloendotheliosis virus Species 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 108091006172 SLC21 Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000021235 Schilder disease Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 244000261559 Smilax china Species 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000005716 Subacute Combined Degeneration Diseases 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- 102000004377 Thiopurine S-methyltransferases Human genes 0.000 description 1
- 108090000958 Thiopurine S-methyltransferases Proteins 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- GXVXXETYXSPSOA-UHFFFAOYSA-N Trapoxin A Natural products C1OC1C(=O)CCCCCC(C(NC(CC=1C=CC=CC=1)C(=O)N1)=O)NC(=O)C2CCCCN2C(=O)C1CC1=CC=CC=C1 GXVXXETYXSPSOA-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- 206010068233 Trimethylaminuria Diseases 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 102000004210 Vitamin K Epoxide Reductases Human genes 0.000 description 1
- 108090000779 Vitamin K Epoxide Reductases Proteins 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- 102100020919 Zinc finger and SCAN domain-containing protein 10 Human genes 0.000 description 1
- 239000005870 Ziram Substances 0.000 description 1
- NMFHJNAPXOMSRX-PUPDPRJKSA-N [(1r)-3-(3,4-dimethoxyphenyl)-1-[3-(2-morpholin-4-ylethoxy)phenyl]propyl] (2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carboxylate Chemical compound C([C@@H](OC(=O)[C@@H]1CCCCN1C(=O)[C@@H](CC)C=1C=C(OC)C(OC)=C(OC)C=1)C=1C=C(OCCN2CCOCC2)C=CC=1)CC1=CC=C(OC)C(OC)=C1 NMFHJNAPXOMSRX-PUPDPRJKSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 208000030597 adult Refsum disease Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- CQIUKKVOEOPUDV-IYSWYEEDSA-N antimycin Chemical compound OC1=C(C(O)=O)C(=O)C(C)=C2[C@H](C)[C@@H](C)OC=C21 CQIUKKVOEOPUDV-IYSWYEEDSA-N 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000028922 artery disease Diseases 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 208000027115 auditory system disease Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- WZSDNEJJUSYNSG-UHFFFAOYSA-N azocan-1-yl-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CCCCCCC2)=C1 WZSDNEJJUSYNSG-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 206010071434 biotinidase deficiency Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- MSZJEPVVQWJCIF-UHFFFAOYSA-N butylazanide Chemical compound CCCC[NH-] MSZJEPVVQWJCIF-UHFFFAOYSA-N 0.000 description 1
- UASRYODFRYWBRC-UHFFFAOYSA-N cGMP Natural products N1C(N)=NC(=O)C2=C1N(C1C3OP(O)(=O)OC3C(CO)O1)C=N2 UASRYODFRYWBRC-UHFFFAOYSA-N 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- 238000001818 capillary gel electrophoresis Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000008809 cell oxidative stress Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 208000009885 central pontine myelinolysis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 108700023145 chlamydocin Proteins 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000010372 cloning stem cell Methods 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 102000038037 druggable proteins Human genes 0.000 description 1
- 108091007999 druggable proteins Proteins 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003174 enzyme fragment complementation Methods 0.000 description 1
- 210000004920 epithelial cell of skin Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002060 fluorescence correlation spectroscopy Methods 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 239000003540 gamma secretase inhibitor Substances 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 208000008605 glucosephosphate dehydrogenase deficiency Diseases 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 201000011205 glycine encephalopathy Diseases 0.000 description 1
- 201000004541 glycogen storage disease I Diseases 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- GNYCTMYOHGBSBI-UHFFFAOYSA-N helminthsporium carbonum toxin Natural products N1C(=O)C(C)NC(=O)C(C)NC(=O)C2CCCN2C(=O)C1CCCCCC(=O)C1CO1 GNYCTMYOHGBSBI-UHFFFAOYSA-N 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000052301 human GNAZ Human genes 0.000 description 1
- 210000000688 human artificial chromosome Anatomy 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 150000001469 hydantoins Chemical class 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 108010090448 insulin gene enhancer binding protein Isl-1 Proteins 0.000 description 1
- 229940068935 insulin-like growth factor 2 Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000025563 intercellular transport Effects 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- DAQAKHDKYAWHCG-RWTHQLGUSA-N lactacystin Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)[C@]1([C@@H](O)C(C)C)NC(=O)[C@H](C)[C@@H]1O DAQAKHDKYAWHCG-RWTHQLGUSA-N 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 101150111214 lin-28 gene Proteins 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 208000014416 lysosomal lipid storage disease Diseases 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 201000003694 methylmalonic acidemia Diseases 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- WDHRPWOAMDJICD-FOAQWNCLSA-N n-[2-[(3'r,3'as,6's,6as,6bs,7'ar,9r,11as,11br)-3',6',10,11b-tetramethyl-3-oxospiro[1,2,4,6,6a,6b,7,8,11,11a-decahydrobenzo[a]fluorene-9,2'-3,3a,5,6,7,7a-hexahydrofuro[3,2-b]pyridine]-4'-yl]ethyl]-6-(3-phenylpropanoylamino)hexanamide Chemical compound C([C@@H](C)C[C@@H]1[C@@H]2[C@H]([C@]3(C(=C4C[C@@H]5[C@@]6(C)CCC(=O)CC6=CC[C@H]5[C@@H]4CC3)C)O1)C)N2CCNC(=O)CCCCCNC(=O)CCC1=CC=CC=C1 WDHRPWOAMDJICD-FOAQWNCLSA-N 0.000 description 1
- OYKBQNOPCSXWBL-SNAWJCMRSA-N n-hydroxy-3-[(e)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide Chemical compound ONC(=O)\C=C\C1=CC=CC(C(=O)NO)=C1 OYKBQNOPCSXWBL-SNAWJCMRSA-N 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 1
- 208000002040 neurosyphilis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 1
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- RZXMPPFPUUCRFN-UHFFFAOYSA-N para-methylaniline Natural products CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 1
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000009120 phenotypic response Effects 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 108010058237 plasma protein fraction Proteins 0.000 description 1
- 229940002993 plasmanate Drugs 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 201000004012 propionic acidemia Diseases 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000001116 retinal neuron Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- 229940080817 rotenone Drugs 0.000 description 1
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- HBROZNQEVUILML-UHFFFAOYSA-N salicylhydroxamic acid Chemical compound ONC(=O)C1=CC=CC=C1O HBROZNQEVUILML-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000002821 scintillation proximity assay Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000002805 secondary assay Methods 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- PDEFQWNXOUGDJR-UHFFFAOYSA-M sodium;2,2-dichloropropanoate Chemical compound [Na+].CC(Cl)(Cl)C([O-])=O PDEFQWNXOUGDJR-UHFFFAOYSA-M 0.000 description 1
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 208000002025 tabes dorsalis Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- BQMKAHQKDSZAIQ-UHFFFAOYSA-N tetrasodium;iron(3+);nitroxyl anion;pentacyanide Chemical compound [Na+].[Na+].[Na+].[Na+].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].O=[N-] BQMKAHQKDSZAIQ-UHFFFAOYSA-N 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108010060597 trapoxin A Proteins 0.000 description 1
- GXVXXETYXSPSOA-UFEOFEBPSA-N trapoxin A Chemical compound C([C@H]1C(=O)N2CCCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)[C@H]1OC1)C1=CC=CC=C1 GXVXXETYXSPSOA-UFEOFEBPSA-N 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- YECWTLGLNDDPGE-PIFXLSLCSA-N trichostatin C Chemical compound C(/[C@@H](C)C(=O)C=1C=CC(=CC=1)N(C)C)=C(/C)\C=C\C(=O)NO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YECWTLGLNDDPGE-PIFXLSLCSA-N 0.000 description 1
- YECWTLGLNDDPGE-UHFFFAOYSA-N trichostatin D Natural products C=1C=C(N(C)C)C=CC=1C(=O)C(C)C=C(C)C=CC(=O)NOC1OC(CO)C(O)C(O)C1O YECWTLGLNDDPGE-UHFFFAOYSA-N 0.000 description 1
- ZSDSQXJSNMTJDA-UHFFFAOYSA-N trifluralin Chemical compound CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O ZSDSQXJSNMTJDA-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 208000030954 urea cycle disease Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
- 108700001624 vesicular stomatitis virus G Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- DUBNHZYBDBBJHD-UHFFFAOYSA-L ziram Chemical compound [Zn+2].CN(C)C([S-])=S.CN(C)C([S-])=S DUBNHZYBDBBJHD-UHFFFAOYSA-L 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
Definitions
- the present invention involves methods for identifying an agent that corrects a phenotype associated with a health condition or a predisposition for a health condition comprising contacting a first population of cells from a human induced pluripotent stem cell line, or cells differentiated from the human induced pluripotent stem cell line, with a candidate agent; contacting a second population of cells from a human induced pluripotent stem cell line, or cells differentiated from the human induced pluripotent stem cell line, with a control agent; wherein the cells in both populations comprise at least one endogenous allele associated with the health condition or predisposition for the health condition; assaying the two populations and identifying candidate agents as correcting the phenotype if the first population is closer to a normal phenotype following treatment than the second population.
- the condition may be selected from health conditions such as a neurodegenerative disorder, a neurological disorder, a mood disorder, a cardiovascular disease, a metabolic disorder, a respiratory disease, a drug sensitivity condition, an eye disease, an immunological disorder, or a hematological disease.
- the cells may be differentiated from induced stem cells to neural stem cells, neurons, cardiomyocytes, hepatic stem cells, or hepatocytes.
- the phenotype described may be apoptosis, intracellular calcium level, calcium flux, protein kinase activity, enzyme activity, cell morphology, receptor activation, protein trafficking, intracellular protein aggregation, organellar composition, motility, intercellular communication, protein expression, or gene expression.
- the invention also involves methods for identifying a diagnostic cellular phenotype comprising comparing a set of cells from a subject to cells from a subject free of the health condition wherein both sets of cells were induced pluripotent stem cells, or were cells differentiated from induced pluripotent stem cells, and wherein the comparison is performed on a computer.
- the cells may be differentiated from induced stem cells to neural stem cells, neurons, cardiomyocytes, hepatic stem cells, or hepatocytes.
- the invention also involves methods for determining the risk of a health condition in a subject comprising comparing at least one phenotype determined in a first set of cells derived from the subject to the at least one phenotype determined in a second set of cells derived from subjects free of the health condition and to the at least one phenotype determined in a third set of cells derived from subjects suffering from the health condition; and indicating that the subject is at high risk for the health condition if the at least one phenotype determined in the first set of cells is more similar to the at least one phenotype determined in the third set of cells than the at least one phenotype determined in the second set of cells, wherein the first, second, and third sets of cells were induced pluripotent stem cells, or were cells differentiated from induced pluripotent stem cells, and wherein the comparison is performed on a computer.
- the invention also involves methods for reducing the risk of drug toxicity in a human subject, comprising contacting one or more cells differentiated from an induced pluripotent stem cell line generated from the subject with a dose of a pharmacological agent, assaying the contacted one or more differentiated cells for toxicity, and prescribing or administering the pharmacological agent to the subject if, and only if, the assay is negative for toxicity in the contacted cells.
- the cells differentiated from the induced pluripotent stem cell line may be hepatocytes, cardiomyocytes, or neurons.
- the invention also involves methods for identifying a candidate gene that contributes to a human disease, comprising comparing a global gene expression profile of cultured human cells of a differentiated cell type from a plurality of healthy individuals to a global gene expression profile of cultured human cells of the differentiated cell type from a plurality of individuals suffering from the human disease and identifying one or more genes that have different expression levels as candidate genes that contribute to the human disease, wherein the comparison is performed on a computer.
- the invention also discloses a human induced pluripotent stem cell line generated from a subject diagnosed as suffering from a health condition, or comprising at least one endogenous allele associated with a health condition or a predisposition for the health condition.
- the invention also discloses an isolated population of human cells comprising neural stem cells or neurons from a subject having at least one endogenous allele associated with a neurodegenerative disorder, a neurological disorder, or a mood disorder, or from a subject diagnosed with the neurodegenerative disorder, neurological disorder, or mood disorder.
- the invention also discloses an isolated population of human cells comprising human cardiac progenitor cells or cardiomyocytes from a subject having at least one endogenous allele associated with a cardiovascular disease, or from a subject diagnosed with the cardiovascular disease.
- the invention also discloses an isolated population of human cells comprising hepatic stem cells or hepatocytes from a subject having at least one endogenous allele associated with a drug sensitivity condition, or from a subject diagnosed with the drug sensitivity condition.
- the invention further discloses a panel of genetically diverse human induced pluripotent stem cell lines, comprising human induced pluripotent stem cell lines generated from a plurality of individuals each of which carry at least one polymorphic allele that is unique among the plurality of individuals.
- Fig. 1 is a schematic comparison of a traditional drug discovery scheme (left) in which lead compounds are tested against a disease target in heterologous systems (e.g., animal models) prior to testing compound efficacy and safety in patients versus a new drug discovery paradigm (right) in which lead compounds are first identified based on their efficacy in correcting a disease-relevant cellular phenotype in patient-derived, disease-relevant cell types.
- heterologous systems e.g., animal models
- FIG. 2 is an overview of an exemplary, non- limiting, scheme for patient iPSC-based disease modeling and drug discovery.
- FIG. 3 is an overview of an exemplary, non- limiting, scheme for patient iPSC-based testing of lead drug candidate efficacy and safety in cells from a genetically diverse cohort of patient iPSC lines.
- FIG. 4 is an overview of an exemplary, non- limiting, scheme for patient iPSC-based identification of predictive biomarkers for drug efficacy and toxicity.
- biomarkers are used in, e.g., patient stratification for clinical trials of drug candidates, and also for optimal dosing and safety of approved therapeutics in specific patients or patient populations, which is sometimes referred to as
- FIG. 5 shows photomicrographs of fibroblasts from three SMNl " ' " SMA patients and two SMN V 1+ healthy control subjects;
- Bottom Panel shows photomicrographs of iPSC colonies derived from the corresponding SMA case and control subject fibroblasts illustrated in the top panel.
- Fig. 6 shows photomicrographs of embryoid bodies obtained from the SMA case and control iPSC lines shown in Fig. 5.
- Fig. 7 shows immunofluorescence photomicrographs of staining for ectodermal (TuJl), mesodermal (Desmin), and endodermal (AFP) lineage markers in cells differentiated from SMlOd iPSCs.
- Genetic variations within and among human patient populations underlie, to a large extent, differences in individual disposition to diseases, disease manifestation, disease severity, and response to treatment (e.g., to drug treatment).
- the prevalent animal and cellular models for human disease and drug discovery provide a poor representation of the genotypic/phenotypic spectrum extant in the patient populations to be treated. For example, strains of mice and rats commonly used in drug discovery are highly inbred, and thus only represent a very narrow range of possible genotype/phenotype combinations in mice or rats, let alone humans.
- the relatively small number of human cell lines used for drug screening may reflect the genotypic/phenotypic scope of the individuals from which they were derived, but not that of a genetically diverse population.
- most human cell lines are quite limited in their capacity to generate or phenocopy specific differentiated cell types (e.g., neurons, cardiomyocytes, and hepatocytes) affected by a particular health condition.
- the cell lines are not representative of cell populations in a subject, since cell lines have been altered to indefinitely replicate.
- animal models or genetically modified cell models of disease simply fail to adequately recapitulate the cellular disease phenotypes as they actually occur in a human patient's cells.
- candidate therapeutic agents are selected for clinical trials in patients based on their action on specific drug targets and their efficacy/lack of toxicity in animal models.
- drug discovery model the disease-relevant cells derived from patient iPSC lines, as described herein, are the starting point for identification of lead compounds based on their ability to ameliorate a disease-relevant cellular phenotype in patient derived cells.
- the present disclosure describes human induced pluripotent stem cell lines from selected individuals (e.g., patients), genetically diverse panels of such cell lines, differentiated cells derived from such cell lines, and methods for their use in disease modeling, drug discovery, diagnostics, and individualized therapy.
- Test drug compound refers to any test compound to be assayed for its ability to affect a functional endpoint.
- functional endpoints are ligand binding to a receptor, receptor antagonism, receptor agonism, protein-protein interactions, enzymatic activities, transcriptional responses, etc.
- iPSC donor refers to a subject, e.g., a human patient from which one or more induced stem cell lines have been generated. Generally, the genome of an iPSC line corresponds to that of its iPSC donor.
- Phenomic analysis refers to the analysis of phenotypes (e.g., resting calcium level, gene expression profiles, apoptotic index, electrophysiological properties, sensitivity to free radicals, compound uptake and extrusion, kinase activity, second messenger pathway responses) exhibited by a particular type of cell (e.g., cardiomyocytes).
- phenotypes e.g., resting calcium level, gene expression profiles, apoptotic index, electrophysiological properties, sensitivity to free radicals, compound uptake and extrusion, kinase activity, second messenger pathway responses.
- Phenome refers to the set of phenotypes that is subject and cell-type specific.
- hepatocytes and cardiomyocytes from the same individual will be quite distinct even though they share the same genome.
- an "endogenous allele,” as used herein, refers to a naturally occurring allele that is native to the genome of a cell, i.e., an allele that is not introduced by recombinant methodologies.
- iPSC-derived cell refers to a cell that is generated from an iPSC either by proliferation of the iPSC to generate more iPSCs, or by differentiation of the iPSC into a different cell type.
- iPSC-derived cells include cells not differentiated directly from an iPSC, but from an intermediary cell type, e.g., a glial progenitor cell, a neural stem cell, or a cardiac progenitor cell.
- a "normal" phenotype refers to a phenotype (e.g., apoptotic rate, resting calcium level, kinase activity, gene expression level) that falls within a range of phenotypes found in healthy individuals or that are not associated with (e.g., predictive of) a health condition.
- a phenotype e.g., apoptotic rate, resting calcium level, kinase activity, gene expression level
- the present disclosure provides human induced pluripotent stem cell (iPSC) lines, panels of stem cell lines, and methods for their use in drug discovery, diagnostic, and therapeutic methods as described in detail below.
- iPSC human induced pluripotent stem cell
- the induced pluripotent stem cell lines disclosed herein are characterized by long term self renewal, a normal karyotype, and the developmental potential to differentiate into a wide variety of cell types (e.g., neurons, cardiomyocytes, and hepatocytes).
- Induced pluripotent stem cell lines can be differentiated into cell lineages of all three germ layers, i.e., ectoderm, mesoderm, and endoderm.
- a subject e.g., a patient
- iPSC lines generated from that subject.
- all of the genotypes of iPSC lines and those of the corresponding subject are identical.
- genotype-phenotype correlations uncovered in one are informative for the other, and vice versa.
- differentiated cells e.g., neurons
- a complete set of cellular phenotypes referred to herein as a "phenome" that are very similar, if not identical, to those of differentiated cells in vivo in the corresponding subject.
- iPSC lines provide a renewable source of differentiated cells (e.g., inaccessible differentiated cells) in which pathological cellular phenotypes that are associated with a disease, cell type, and individual may be examined and screened against test compounds.
- iPSC lines and iPSC-derived cells are also useful for predicting the efficacy and/or adverse side effects of a candidate drug compound in specific individuals or groups of individuals, as schematically illustrated in Fig. 3.
- test compounds can be tested for toxicity in hepatocytes differentiated from a genetically diverse panel of induced pluripotent stem cells. Toxicity testing in iPSC-derived hepatocytes can reveal both the overall likelihood of toxicity of a test compound in a target patient population, and the likelihood of toxicity in specific patients within that population.
- iPSC lines and iPSC-derived cells can serve as "cellular avatars," that reveal cellular phenotypes that are disease, cell-type, and subject-specific to the extent the phenotypes are determined or predisposed by the genome.
- panels of patient induced stem cell lines will represent a wide range of genotype/phenotype combinations in a patient population. Thus, they are useful for developing therapeutics that are effective and safe across a wide range of the relevant target population, or for determining which individuals can be treated effectively and safely with a given therapeutic agent.
- Some of the methods described herein utilize induced stem cell lines or panels of induced stem cell lines derived from subjects that meet one or more pre-determined criteria. In some cases subjects and cellular samples from such subjects may be selected for the generation of induced stem cell lines and panels of induced stem cell lines based on one or more of such pre-determined criteria.
- a health condition in a subject e.g, spinal muscular atrophy, Parkinson's disease, or amyotrophic lateral sclerosis
- a health condition e.g, spinal muscular atrophy, Parkinson's disease, or amyotrophic lateral sclerosis
- one or more positive diagnostic criteria for a health condition e.g, spinal muscular atrophy, Parkinson's disease, or amyotrophic lateral sclerosis
- a family medical history indicating a predisposition or recurrence of a health condition
- the presence or absence of a genotype associated with a health condition e.g., the presence or absence of a genotype associated with a health condition
- the presence of at least one polymorphic allele that is not already represented in a panel of induced stem cell lines e.g, a panel of induced stem cell lines is generated specifically from individuals diagnosed with a health condition, and from subjects that are free of the health condition.
- Such health conditions include, without limitation, neurodegenerative disorders; neurological disorders such as cognitive impairment, and mood disorders; auditory disease such as deafness; osteoporosis; cardiovascular diseases; diabetes; metabolic disorders; respiratory diseases; drug sensitivity conditions; eye diseases such as macular degeneration; immunological disorders; hematological diseases; kidney diseases; proliferative disorders; genetic disorders, traumatic injury, stroke, organ failure, or loss of limb.
- neurodegenerative disorders include, but are not limited to, Alexander's disease, Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis, ataxia telangiectasia, Batten disease, bovine spongiform encephalopathy, Canavan disease, Cockayne syndrome, corticobasal degeneration, Creutzfeldt- Jakob disease, Huntington's disease, HIV-associated dementia, Kennedy's disease, Krabbe's disease, lewy body dementia, Machado-Joseph disease, multiple sclerosis, multiple system atrophy, narcolepsy, neuroborreliosis, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick's disease, primary lateral sclerosis, prion diseases, Refsum's disease, Sandhoff s disease, Schilder's disease, subacute combined degeneration of spinal cord secondary to pernicious anaemia, schizophrenia, spinocerebellar ataxia, spinal muscular atrophy
- Examples of neurological disorders include, stroke, cognitive impairment, and mood disorders.
- Examples of immunological disorders include but are not limited to acquired immune deficiency, leukemia, lymphoma, hypersensitivities (allergy), autoimmune diseases, and severe combined immune deficiency.
- autoimmune diseases include but are not limited to acute disseminated encephalomyelitis, addison's disease, ankylosing spondylitis, antiphospholipid antibody syndrome, autoimmune hemolytic anemia, autoimmune hepatitis, bullous pemphigoid, coeliac disease, dermatomyositis, diabetes mellitus type 1 , Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, idiopathic thrombocytopenic purpura, lupus erythematosus, multiple sclerosis, myasthenia gravis, pemphigus, pernicious anaemia, polymyositis, primary biliary cirrhosis, rheumatoid arthritis, Sjogren's syndrome, temporal arthritis (also known as "giant cell arthritis”), vasculitis, Wegener's granulomatosis.
- cardiovascular diseases include but are not limited to aneurysm, angina, arrhythmia, atherosclerosis, cardiomyopathy, cerebrovascular accident (stroke), cerebrovascular disease, congenital heart disease, congestive heart failure, myocarditis, valve disease coronary, artery disease dilated, cardiomyopathy, diastolic dysfunction, endocarditis, high blood pressure (hypertension), hypertrophic cardiomyopathy, mitral valve prolapse, myocardial infarction (heart attack), and venous thromboembolism.
- stroke cerebrovascular accident
- congenital heart disease congestive heart failure
- myocarditis valve disease coronary, artery disease dilated
- cardiomyopathy diastolic dysfunction
- endocarditis high blood pressure (hypertension)
- hypertrophic cardiomyopathy mitral valve prolapse
- myocardial infarction heart attack
- venous thromboembolism examples include but are not limited to aneurysm, angina, arrhythmia
- metabolic disorders include but are not limited to acid lipase disease, amyloidosis, Barth Syndrome, biotinidase deficiency, carnitine palmitoyl transferase deficiency type II, central pontine myelinolysis, metabolic diseases of muscle including muscular dystrophy, Farber's Disease, glucose-6- phosphate dehydrogenase deficiency, gangliosidoses, trimethylaminuria, Lesch-Nyhan syndrome, lipid storage diseases, metabolic myopathies, methylmalonic aciduria, mitochondrial myopathies, mucopolysaccharidoses, mucolipidoses, mucolipidoses, mucopolysaccharidoses, multiple CoA carboxylase deficiency, nonketotic hyperglycinemia, Pompe disease, propionic acidemia, type I glycogen storage disease, urea cycle disorders, hyperoxaluria, and oxalosis.
- proliferative disorders include but are not limited to one or more of the following: carcinomas, sarcomas, lymphomas, leukemias, germ cell tumors, blastic tumors, prostate cancer, lung cancer, colorectal cancer, bladder cancer, cutaneous melanoma, breast cancer, endometrial cancer, and ovarian cancer.
- Such subjects may be identified in, e.g., gene association studies, clinical studies, and hospitals, preferably after a final diagnosis of a health condition has been made.
- subjects are identified in gene association studies that include non-affected control individuals.
- iPSC lines are generated from subjects screened for the presence or absence of at least one allele associated with a health condition or a predisposition for a health condition.
- Such alleles indicate that an individual, though not exhibiting overt symptoms of a health condition, has a high risk of developing the health condition.
- BRCAl have been used to indicate a high likelihood of developing breast cancer. Genotyping of subjects may be performed on samples from a number of sources, e.g., blood banks, sperm banks, gene-association studies, hospitals, clinical trials, or any other source as long as a living cellular sample can be obtained from the individual that is genotyped.
- cellular phenotypes from individuals carrying alleles associated with health conditions will exhibit abnormalities that can serve as more reliable prognostic indicators of a health condition in combination with a genotype than a genotype alone. Further, identification of specific abnormal cellular phenotypes associated with a health condition may indicate a target pathway for screening of prophylactic and therapeutic agents for the health condition.
- SNPs single polymorphisms
- common health conditions e.g., neurodegenerative diseases, psychiatric disorders, metabolic disorders, and cardiovascular diseases.
- Subjects may be screened for alleles in genes that affect response to a therapeutic agent or to a class of therapeutic agents.
- alleles include, but are not limited to, alleles of drug metabolizing enzymes, such as Glucose 6 phosphate dehydrogenase (G6PDH), Butyrlcholine esterase, N-acetyltransferase, Cytochrome P450 isoforms (e.g., 2B6, 2D6, C19, 2C9), Thiopurine S- methyltransferase, Dihydropyrimidine dehydrogenase, and Uridin diphospho-glucuronic acid transferase type IAl.
- G6PDH Glucose 6 phosphate dehydrogenase
- Butyrlcholine esterase N-acetyltransferase
- Cytochrome P450 isoforms e.g., 2B6, 2D6, C19, 2C9
- Alleles of Cytochrome P450 enzyme isoforms can be found, e.g., in a database provided under the " Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee," at "www.cypalleles.ki.se/.”
- Some alleles occur in genes that affect drug transport, including, e.g., multiple drug resistance conferring transporters (MDRs), breast cancer resistance protein (BRCP), multidrug resistance-associated-associated proteins (MRPs), and organic anion-transporting polypeptide (OATPlBl).
- MDRs multiple drug resistance conferring transporters
- BRCP breast cancer resistance protein
- MRPs multidrug resistance-associated-associated proteins
- OATPlBl organic anion-transporting polypeptide
- Other alleles occur in genes that encode drug targets, including, but not limited to, Vitamin K epoxide reductase, Factor V, G-protein coupled receptors (GPCRs).
- GPCRs are one of the most common drug targets.
- polymorphic alleles in GPCRs can be found in, e.g., the GPCR Natural Variants ("NaVa”) Database, which is accessible on the internet at "nava.liacs.nl/"
- GPCR NaVa GPCR Natural Variants
- the GPCR NaVa database describes sequence variants within the family of human G Protein-Coupled Receptors (GPCRs). It includes: rare mutations (frequency ⁇ 1%); polymorphisms (frequency > 1%), including Single Nucleotide Polymorphisms (SNPs); variants without estimates of allele frequency.
- Polymorphic alleles of interest may be detected and scored in a nucleic acid sample from a subject by any of a number of methods known in the art. For example, detection of multiple alleles may be performed by conducting a nucleic acid array-based assay on a nucleic acid sample from a subject, where the nucleic acid array comprises allele-specific probes (e.g., SNP-specific probes), which, under high stringency hybridization conditions, selectively hybridize with and discriminate between the nucleic acid sequences of two or more polymorphic alleles of interest, e.g., alleles of G-protein coupled receptors.
- allele-specific probes e.g., SNP-specific probes
- the nucleic acid arrays used to detect polymorphisms may be commercially available nucleic acid arrays.
- the Affymetrix ® Genome-Wide SNP Array 6.0 includes probes for more than 906,000 SNPs and more than 946,000 probes for the detection of copy number variation.
- the nucleic acid arrays may be custom-made to include to a limited subset of alleles of interest.
- the design of suitable probe arrays for analysis of predetermined polymorphisms and interpretation of the hybridization patterns is described in detail in WO 95/11995; EP 717,113; and WO 97/29212.
- Such arrays typically contain first and second groups of probes which are designed to be complementary to different allelic forms of the polymorphism.
- Each group contains a first set of probes, which is subdivided into subsets, one subset for each polymorphism.
- Each subset contains probes that span a polymorphism and proximate bases and are complementary to one allelic form of the polymorphism.
- the hybridization patterns of these probes to target samples can be analyzed by footprinting or cluster analysis, as described above.
- first and second probes groups contain subsets of probes respectively complementarity to first and second allelic forms of a polymorphic site spanned by the probes
- first and second probes groups contain subsets of probes respectively complementarity to first and second allelic forms of a polymorphic site spanned by the probes
- on hybridization of the array to a sample that is homozygous for the first allelic form all probes in the subset from the first group show specific hybridization, whereas probes in the subset from the second group that span the polymorphism show only mismatch hybridization.
- the mismatch hybridization is manifested as a footprint of probe intensities in a plot of normalized probe intensity (i.e., target/reference intensity ratio) for the subset of probes in the second group.
- a footprint is observed in the normalized hybridization intensities of probes in the subset from the first probe group. If the target sample is heterozygous for both allelic forms then a footprint is seen in normalized probe intensities from subsets in both probe groups although the depression of intensity ratio within the footprint is less marked than in footprints observed with homozygous alleles.
- Analysis of the hybridization pattern of a nucleic acid array to a nucleic acid sample indicates which allelic form is present at some or all of the SNP sequences represented on the array.
- an individual or an iPSC line generated from an individual can be characterized with a polymorphic profile representing allelic variants of interest, e.g., alleles associated with a health condition.
- an allele is detected using a primer extension reaction or amplification reaction.
- a nucleic acid sample containing (or suspected of containing) a target nucleic acid molecule can be contacted with an oligonucleotide primer that, upon further contact with a polymerase, can be extended up to and, if desired, beyond the position of the SNP.
- the nucleic acid sample can be contacted with an amplification primer pair, comprising a first primer and a second primer, which selectively hybridize to complementary strands of a target nucleic acid molecule and, in the presence of polymerase, allow for generation of an amplification product.
- primers of an amplification primer pair are referred to as a "first primer” and a “second primer”; however, reference herein to a “first primer” or a “second primer” is not intended to indicate any importance, order of addition, or the like. It will be further recognized that an amplification primer pair requires that the first and second primer comprise what are commonly referred to as a forward primer and a reverse primer.
- a primer extension or PCR amplification reaction can be designed such that the presence of a particular nucleotide at an SNP position can be determined by the presence or size of the extension and/or amplification product, in which case the SNP can be determined using a method such as gel electrophoresis, capillary gel electrophoresis, or mass spectrometry; or the amplification product can be sequenced to determine the nucleotide at the SNP position.
- the SNP can be detected indirectly, for example, by further contacting the sample with a detector oligonucleotide, which can selectively hybridize to a nucleotide sequence of the first amplification product comprising the SNP position; and detecting selective hybridization of the detector oligonucleotide, as above.
- a detector oligonucleotide which can selectively hybridize to a nucleotide sequence of the first amplification product comprising the SNP position; and detecting selective hybridization of the detector oligonucleotide, as above.
- PCR can be performed using TaqMan ® reagents, followed by reading the plates at this endpoint.
- Amplification products also can be detected using an ELISA format, for example, using a design in which one primer is biotinylated and the other contains digoxygenin.
- the amplification products are then bound to a streptavidin plate, washed, reacted with an enzyme-conjugated antibody to digoxygenin, and developed with a chromogenic, fluorogenic, or chemiluminescent substrate for the enzyme.
- a radioactive method can be used to detect generated amplification products, for example, by including a radiolabeled deoxynucleoside triphosphate into the amplification reaction, then blotting the amplification products onto DEAE paper for detection.
- chemiluminescent label for example, a lanthanide chelate such as used in the DELFIA ® assay (Pall Corp.), an electrochemiluminescent label such as ruthenium tris-bipyridy (ORI-GEN), or a fluorescent label, for example, using fluorescence correlation spectroscopy.
- a chemiluminescent label for example, a lanthanide chelate such as used in the DELFIA ® assay (Pall Corp.), an electrochemiluminescent label such as ruthenium tris-bipyridy (ORI-GEN), or a fluorescent label, for example, using fluorescence correlation spectroscopy.
- SNP-IT ® assay system An assay system that is commercially available and can be used to identify a nucleotide occurrence of one or more SNPs is the SNP-IT ® assay system (Orchid BioSciences, Inc.; Princeton N. J.).
- the SNP-IT ® method is a three step primer extension reaction. In the first step a target nucleic acid molecule is isolated from a sample by hybridization to a capture primer, which provides a first level of specificity. In a second step the capture primer is extended from a terminating nucleotide triphosphate at the target SNP site, which provides a second level of specificity.
- the extended nucleotide triphosphate can be detected using a variety of known formats, including, for example, by direct fluorescence, indirect fluorescence, an indirect colorimetric assay, mass spectrometry, or fluorescence polarization. Reactions conveniently can be processed in 384 well format in an automated format using a SNP stream ® instrument (Orchid BioSciences, Inc.).
- Various methods for genotyping SNP alleles are readily adaptable to high throughput assays.
- an amplification reaction such as PCR can be performed using inexpensive robotic thermocyclers for a specified number of cycles, then the amplification product generated can be determined at the endpoint of the reaction.
- the methods can be performed in a multiplex format, for example, using differentially labeled oligonucleotide probes, or performing oligonucleotide ligation assays that result in different sized ligation products, or amplification reactions that result in different sized amplification products.
- high-throughput mass spectrometry is used to detect SNP alleles in a target nucleic acid sample. Mass spectrometric methods for SNP genotyping are described in, e.g., U.S. Patent Nos: 7,132,519, 6,994,998; and U.S. Patent Application No 20060275789.
- high stringency conditions are those that result in perfect matches remaining in hybridization complexes, while imperfect matches melt off.
- low stringency conditions are those that allow the formation of hybridization complexes with both perfect and imperfect matches.
- High stringency conditions are known in the art; see for example Maniatis et al. (1989), Molecular Cloning: A Laboratory Manual, 2d Edition; and Short Protocols in Molecular Biology, ed. Ausubel, et al. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures.
- Tm thermal melting point
- Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30 C for short probes (e.g. 10 to 50 nucleotides) and at least about 60 C for long probes (e.g. greater than 50 nucleotides).
- Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.
- less stringent hybridization conditions are used; for example, moderate or low stringency conditions may be used, as are known in the art. See, e.g., Maniatis and Ausubel, supra, and Tijssen, supra.
- iPSC lines may be induced from a wide variety of mammalian cells, e.g., human somatic cells, such as fibroblasts, bone marrow-derived mononuclear cells, skeletal muscle cells, adipose cells, peripheral blood mononuclear cells, macrophages, hepatocytes, keratinocytes, oral keratinocytes, hair follicle dermal cells, gastric epithelial cells, lung epithelial cells, synovial cells, kidney cells, skin epithelial cells or osteoblasts.
- mammalian cells e.g., human somatic cells, such as fibroblasts, bone marrow-derived mononuclear cells, skeletal muscle cells, adipose cells, peripheral blood mononuclear cells, macrophages, hepatocytes, keratinocytes, oral keratinocytes, hair follicle dermal cells, gastric epithelial cells, lung epithelial cells, syn
- the cells to be induced can originate from many different types of tissue, e.g., bone marrow, skin
- the cells can also be derived from neonatal tissue, including, but not limited to: umbilical cord tissues (e.g., the umbilical cord, cord blood, cord blood vessels), the amnion, the placenta, or other various neonatal tissues (e.g., bone marrow fluid, muscle, adipose tissue, peripheral blood, skin, skeletal muscle etc.).
- umbilical cord tissues e.g., the umbilical cord, cord blood, cord blood vessels
- the amnion e.g., the placenta
- other various neonatal tissues e.g., bone marrow fluid, muscle, adipose tissue, peripheral blood, skin, skeletal muscle etc.
- the cells can be derived from neonatal or post-natal tissue collected from a mammal within the period from birth, including cesarean birth, to death.
- the tissue may be from a mammal who is > 10 minutes old, > 1 hour old, > 1 day old, > 1 month old, > 2 months old, > 6 months old, > 1 year old, >2 years old, >5 years old, >10 years old, >15 years old, >18 years old, >25 years old, >35 years old, >45 years old, >55 years old, >65 years old, ⁇ 80 years old, ⁇ 70 years old, ⁇ 60 years old, ⁇ 50 years old, ⁇ 40 years old, ⁇ 30 years old, ⁇ 20 years old or ⁇ 10 years old.
- the tissue is from a human age 18, 20, 21, 23, 24, 25, 28, 29, 31, 33, 34, 35, 37, 38, 40, 41, 42, 43, 44, 47, 51, 55, 61, 63, 65, 70, 77, or 85 years old.
- the cells may be from non-embryonic tissue, e.g., at a stage of development later than the embryonic stage.
- the cells may be derived from a fetus.
- the cells are not from a fetus.
- the cells are from an embryo. In some cases, the cells are not from an embryo.
- the cells can be obtained from a single cell or a population of cells.
- the population may be homogenous or heterogeneous.
- the cells may be a population of cells found in a human cellular sample, e.g., a biopsy or blood sample.
- the cells are a cell line.
- the cells are somatic cells.
- the cells are derived from cells fused to other cells.
- the cells are not derived from cells fused to other cells.
- the cells are not derived from cells artificially fused to other cells.
- the cells are not: a cell that has been fused with an embryonic stem cell, or a cell that has undergone the procedure known as somatic cell nuclear transfer.
- the cellular population may include both differentiated and undifferentiated cells. In some cases, the population primarily contains differentiated cells. In other cases, the population primarily contains undifferentiated cells, e.g., undifferentiated stem cells. The undifferentiated cells within the population may be induced to become pluripotent or multipotent. In some cases, differentiated cells within the cellular population are induced to become pluripotent or multipotent. [0063] The cellular population may include undifferentiated cells such as mesenchymal stem cells (MSCs), see, e.g., Pittenger et al.
- MSCs mesenchymal stem cells
- MSCs multipotent adult progenitor cells
- MIAMI marrow-isolated adult multilineage inducible cells
- the undifferentiated stem cells are stem cells that have not undergone epigenetic inactivating modification by heterochromatin formation due to DNA methylation or histone modification of at least four genes, at least three genes, at least two genes, at least one gene, or none of the following: Nanog, Oct3/4, Sox2 and Tert.
- Activation, or expression of such genes may occur when human pluripotent stem cells are induced from undifferentiated stem cells present in a human postnatal tissue.
- Methods for obtaining human somatic cells are well established, as described in, e.g., Schantz and Ng (2004), A Manual for Primary Human Cell Culture, World Scientific Publishing Co., Pte, Ltd.
- the methods include obtaining a cellular sample, e.g., by a biopsy, blood draw, or alveolar or other pulmonary lavage.
- Other suitable methods for obtaining various types of human somatic cells include, but are not limited to, the following exemplary methods:
- the donor is given a general anesthetic and placed in a prone position. From the posterior border of the ilium, a collection needle is inserted directly into the skin and through the iliac surface to the bone marrow, and liquid from the bone marrow is aspirated into a syringe. A mononuclear cell fraction is then prepared from the aspirate by density gradient centrifugation. The collected crude mononuclear cell fraction is then cultured prior to use in the methods described herein for induction pluripotency. For convenience, methods for induction of pluripotency, as described herein, are collectively referred to as "induction.”
- Skin tissue containing the dermis is harvested, for example, from the back of a knee or buttock. The skin tissue is then incubated for 30 minutes at 37 ° C in 0.6% trypsin/DMEM (Dulbecco's Modified Eagle's Medium)/F-12 with 1% antibiotics/antimycotics, with the inner side of the skin facing downward. [0067] After the skin tissue is turned over to scrub slightly the inner side with tweezers, the skin tissue is finely cut into 1 mm2 sections using scissors, which are then centrifuged at 1200 rpm and room temperature for 10 minutes.
- trypsin/DMEM Dynabecco's Modified Eagle's Medium
- F-12 1% antibiotics/antimycotics
- tissue precipitate is added 25 ml of 0.1% trypsin/DMEM/F-12/1% antibiotics, antimycotics, and stirred using a stirrer at 37°C and 200-300 rpm for 40 minutes.
- 3 ml fetal bovine serum (FBS) (manufactured by JRH) is added, and filtered sequentially with gauze (Type I manufactured by PIP), a 100 ⁇ m nylon filter (manufactured by FALCON) and a 40 ⁇ m nylon filter (manufactured by FALCON).
- DMEM/F-12/1% antibiotics, antimycotics is added to wash the precipitate, and then centrifuged at 1200 rpm and room temperature for 10 minutes. The cell fraction thus obtained is then cultured prior to induction.
- a connective tissue containing muscle such as the lateral head of the biceps brachii muscle or the sartorius muscle of the leg is cut and the muscle tissue is excised, it is sutured.
- the whole muscle obtained is minced with scissors or a scalpel, and then suspended in DMEM (high glucose) containing 0.06% collagenase type IA and 10% FBS, and incubated at 37°C for 2 hours.
- DMEM high glucose
- the cell fraction obtained may be cultured according to the method described in 6. below as crude purified cells containing undifferentiated stem cells, and used for the induction of human pluripotent stem cells of the present invention.
- Cells derived from adipose tissue for use in the present invention may be isolated by various methods known to a person skilled in the art. For example, such a method is described in U.S. Pat. No.
- adipose tissue is omental adipose tissue.
- adipose cells are typically isolated by fat aspiration.
- adipose tissue is treated with 0.01% to 0.5%, preferably 0.04% to 0.2%, and most preferably about 0.1% collagenase, 0.01% to 0.5%, preferably 0.04%, and most preferably about 0.2% trypsin and/or 0.5 ng/ml to 10 ng/ml dispase, or an effective amount of hyaluronidase or DNase (DNA digesting enzyme), and about 0.01 to about 2.0 mM, preferably about 0.1 to about 1.0 mM, most preferably 0.53 mM concentration of ethylenediaminetetraacetic acid (EDTA) at 25 to 50 0 C, preferably 33 to 40 0 C, and most preferably 37°C for 10 minutes to 3 hours, preferably 30 minutes to 1 hour, and most preferably 45 minutes.
- EDTA ethylenediaminetetraacetic acid
- Cells are passed through nylon or a cheese cloth mesh filter of 20 microns to 800 microns, more preferably 40 microns to 400 microns, and most preferably 70 microns. Then the cells in the culture medium are subjected to differential centrifugation directly or using Ficoll or Percoll or another particle gradient. The cells are centrifuged at 100 to 3000 ⁇ g, more preferably 200 to 1500 ⁇ g, most preferably
- the adipose tissue-derived cell fraction thus obtained may be cultured according to the method described herein as crude purified cells containing undifferentiated stem cells, and used for the induction of human pluripotent or multipotent stem cells.
- peripheral blood-derived or cord blood-derived adherent cell fraction thus obtained may be cultured according to the method described herein as crude purified cells containing undifferentiated stem cells, and used for the induction of human pluripotent stem cells of the present invention.
- the induction process forced expression of certain polypeptides is carried out in cultured cells for a period of time, after which the iPSCs are screened for a number of morphological and gene expression properties that characterize multipotent and pluripotent stem cells. Induced cells that meet these screening criteria may then be subcloned and expanded.
- the cells to be induced may be cultured for a period of time prior to the induction procedure. Alternatively, the cells to be induced may be used directly in the induction process without a prior culture period.
- the type of cell culture medium used is the same or very similar before, during, and after the induction process. In other cases, different cell culture media are used at different points. For example, one type of culture medium may be used directly before the induction process, while a second type of media is used during the induction process. At times, a third type of culture medium is used during the induction process.
- Cells may be cultured in medium supplemented with a particular serum.
- the serum is fetal bovine serum (FBS).
- the serum can also be fetal calf serum (FCS).
- the serum may be Human AB serum .
- Mixtures of serum may also be used, e.g. mixture of FBS and Human AB, FBS and FCS, or FCS and Human AB.
- a "low serum culture condition" refers to the use of a cell culture medium containing a concentration of serum ranging from 0% (v/v) (i.e., serum- free) to about 5% (v/v), e.g., 0% to 2%, 0% to 2.5%, 0% to 3%, 0% to 4%, 0% to 5%, 0.1% to 2%, 0.1% to 5%, 0.1%, 0.5%, 1%, 1.2%, 1.5%, 2%, 2.5%, 3%, 3.5%, or 4%.
- the serum concentration is from about 0% to about 2%. In some cases, the serum concentration is about 2%.
- the serum concentration is preferably 2% or less.
- cells are cultured under a "high serum condition," i.e., greater than 5% serum to about 20% serum, e.g., 6%, 7%, 8%, 10%, 12%, 15%, or 20%.. Culturing under high serum conditions may occur prior to, during, and/or after induction.
- Some representative media that the cells can be cultured in include: MAPC, FBM, ES, MEF- conditioned ES (MC-ES), and mTeSRTM (available, e.g., from StemCell Technologies, Vancouver, Canada), See Ludwig et al (2006), Nat Biotechnol, 24(2): 185- 187.
- alternative culture conditions for growth of human ES cells are used, as described in, e.g., Skottman et al (2006), Reproduction, 132(5):691-698.
- the cells are cultured in MAPC, FBM, MC-ES, or mTeSRTM prior to and/or during the introduction of induction factors to the cells; and the cells are cultured in MC-ES or mTeSRTM medium later in the induction process.
- MAPC (2% FBS) Medium may comprise: 60% Dulbecco's Modified Eagle's Medium-low glucose, 40% MCDB 201, Insulin Transferrin Selenium supplement, (0.01 mg/ml insulin; 0.0055 mg/ml transferrin; 0.005 ⁇ g/ml sodium selenite), IX linolenic acid albumin (1 mg/mL albumin; 2 moles linoneic acid/mole albumin), 1 nM dexamethasone, 2% fetal bovine serum, 1 nM dexamethasone, 10-4 M ascorbic acid, and 10 ⁇ g/ml gentamycin.
- FBM (2% FBS) Medium may comprise: MCDB202 modified medium, 2% fetal bovine serum, 5 ⁇ g/ml insulin, 50 mg/ml gentamycin, and 50 ng/ml amphotericin-B.
- ES Medium may comprise: 40% Dulbecco's Modified Eagle's Medium (DMEM) 40% F12 medium, 2 mM L-glutamine, IX non-essential amino acids (Sigma, Inc., St. Louis, MO), 20% Knockout Serum ReplacementTM (Invitrogen, Inc., Carlsbad, CA), and 10 ⁇ g/ml gentamycin.
- DMEM Dulbecco's Modified Eagle's Medium
- F12 medium 2 mM L-glutamine
- IX non-essential amino acids Sigma, Inc., St. Louis, MO
- Knockout Serum ReplacementTM Invitrogen, Inc., Carlsbad, CA
- 10 ⁇ g/ml gentamycin 10 ⁇ g/ml gentamycin.
- ES medium is conditioned on mitomycin C-treated murine embryonic fibroblasts (MEFs ), harvested, filtered through a 0.45- ⁇ M filter, and supplemented with about 0.1 mM ⁇ mercaptoethanol, about 10 ng/ml bFGF or FGF-2, and, optionally, about 10 ng/ml activin A.
- MEFs murine embryonic fibroblasts
- irradiated MEFs are used in place of the mitomycin C-treated MEFs.
- one or more growth factors such as fibroblast growth factor (FGF)-2; basic FGF (bFGF); platelet-derived growth factor (PDGF), epidermal growth factor (EGF); insulin-like growth factor (IGF); or insulin can be included in the culture medium.
- Other growth factors that can be used to supplement cell culture media include, but are not limited to one or more: Transforming Growth Factor ⁇ -1 (TGF ⁇ -1 ), Activin A, Noggin, Brain- derived Neurotrophic Factor (BDNF ), Nerve Growth Factor (NGF), Neurotrophin (NT)-I, NT-2, or NT 3.
- TGF ⁇ -1 Transforming Growth Factor ⁇ -1
- BDNF Brain- derived Neurotrophic Factor
- NGF Nerve Growth Factor
- NT Neurotrophin
- NT Neurotrophin
- the concentration of growth factors in the culture media described herein is from about 2 ng/ml to about 20 ng/ml , e.g., about 2 ng/ml, 3 ng/ml, 4 ng/ml,5 ng/ml, 6 ng/ml, 7 ng/ml, 8 ng/ml, 10 ng/ml, 12 ng/ml, 14 ng/ml, 15 ng/ml, 17 ng/ml, or 20 ng/ml.
- the concentration of of bFGF or FGF2 is from about 2 ng/ml to about 5 ng/ml; from about 5 ng/ml to about 8 ng/ ml; from about 9 ng/ml to about 11 ng/ml; from about 11 ng/ml to about 15 ng/ml; or from about 15 ng/ml to about 20 ng/ml.
- the growth factors may be used alone or in combination.
- FGF-2 may be added alone to the medium; in another example, both PDGF and EGF are added to the culture medium .
- the "iPSCs" are maintained in MC-ES medium as described herein.
- cells are maintained in the presence of a rho, or rho-associated, protein kinase (ROCK) inhibitor to reduce apoptosis.
- ROCK protein kinase
- an inhibitor of Rho associated kinase is added to the culture medium.
- Y-27632 Calbiochem; water soluble
- Fasudil HAl 077: Calbiochem
- an inhibitor of Rho associated kinase Rho associated coiled coil- containing protein kinase
- concentration of Y-27632 or Fasudil is from about 5 ⁇ M to about 20 ⁇ M, e.g., about 5 ⁇ M, 10 ⁇ M, 15 ⁇ M, or 20 ⁇ M.
- the cells may be cultured for about 1 to about 12 days e.g., 2 days, 3 days, 4.5 days, 5 days, 6.5 days, 7 days, 8 days, 9 days, 10 days, or any other number of days from about lday to about 12 days prior to undergoing the induction methods described herein.
- the iPSCs are cultured in complete ES medium in a 37°C, 5% CO 2 incubator, with medium changes about every 1 to 2 days.
- induced the iPSCs are cultured and observed for about 14 days to about 40 days, e.g., 15, 16, 17, 18, 19, 20, 23, 24, 27, 28, 29, 30, 31, 33, 34, 35, 36, 37, 38 days, or any other period from about 14 days to about 40 days prior to identifying and selecting clones comprising "iPSCs" based on morphological characteristics.
- Morphological characteristics for identifying iPSC clones include, but are not limited to, a small cell size with a high nucleus-to-cytoplasm ratio; formation of small monolayer colonies within the space between parental cells (e.g., between fibroblasts).
- the cells may be plated at a cell density of about 1 x 10 3 cells/cm 2 to about 1 x 10 4 cells/cm 2 , e.g., 2 x 10 3 cells/cm 2 , 3.5 x 10 3 cells/cm 2 , 6 x 10 3 cells/cm 2 , 7 x 10 3 cells/cm 2 , 9 x 10 3 cells/cm 2 , or any other cell density from about 1 x 10 3 cells/cm 2 to about 1 x 10 4 cells/cm 2 .
- the cells can be plated and cultured directly on tissue culture-grade plastic.
- cells are plated and cultured on a coated substrate, e.g., a substrate coated with fibronectin, gelatin, matrigelTM, collagen, or laminin.
- Suitable cell culture vessels include, e.g., 35 mm, 60 mm, 100 mm, and 150 mm cell culture dishes, 6-well cell culture plates, and other size-equivalent cell culture vessels.
- the cells are cultured with feeder cells.
- the cells may be cultured on a layer, or carpet, of MEFs .
- Media with low concentrations of serum may be particularly useful to enrich for undifferentiated stem cells.
- the undifferentiated cells cultured under low serum conditions may or may not share certain properties with MSCs, MAPCs, and/or MIAMI cells. Differences in phenotype may be due, in part, to culture methods used to obtain MSCs, MAPCs and MIAMI cells.
- MSCs are often obtained by isolating the non-hematopoeitic cells (e.g., interstitial cells) adhering to a plastic culture dish when tissue, e.g.,bone marrow, fat, muscle, or skin etc., is cultured in a culture medium containing a high- concentration serum (5% or more).
- the cells in order to culture and grow human pluripotent stem cells induced from the undifferentiated stem cells of the present invention present in a human postnatal tissue, it is preferred that the cells are subcultured every 5 to 7 days in a culture medium containing the additives described herein on a MEF-covered plastic culture dish or a matrigel-coated plastic culture dish. In some cases, the cells may be cultured at a low density, which may be accomplished by splitting the cells from about 1 :6 to 1 :3 or by plating the cells at 10 3 cells/cm 2 to 3 x 10 4 cells/cm 2 .
- Primary culture ordinarily occurs immediately after the cells are isolated from a donor, .e.g., human.
- the primary cells can be subjected to a second subculture, a third subculture, a fourth subculture, and greater than four subcultures.
- a "second" subculture describes primary culture cells subcultured once
- a "third” subculture describes primary cultures subcultured twice
- a "fourth” subculture describes primary cells subcultured three times, etc.
- the culture techniques described herein may generally include culturing from the period between the primary culture and the fourth subculture, but other culture periods may also be employed.
- cells are cultured from primary culture to second subculture.
- Inducing a cell to become pluripotent can be accomplished in numerous ways.
- the methods for induction of pluripotency in one or more cells include forcing expression of a set of induction factors (IFs).
- the set of IFs includes one or more: an Oct3/4 polypeptide, a Sox2 polypeptide, a Klf4 polypeptide, or a c-Myc polypeptide.
- the set does not include a c-Myc polypeptide.
- the set of IFs can include: an Oct3/4 polypeptide, a Sox2 polypeptide, and a Klf4 polypeptide, but not a c-Myc polypeptide.
- the set of IFs does not include polypeptides that might increase the risk of cell transformation.
- the set may include a c-Myc polypeptide.
- the c-Myc polypeptide is a constitutive Iy active variant of c-Myc.
- the set includes a c-Myc polypeptide capable of inducible activity, e.g., a c-Myc-ER polypeptide, see, e.g., Littlewood, et al. (1995) Nucleic Acid Res. 23(10):1686-90.
- the set of IFs may include: an Oct3/4 polypeptide, a Sox2 polypeptide, and a Klf4 polypeptide, but not a TERT polypeptide, a SV40 Large T antigen polypeptide, HPV 16 E6 polypeptide, a HPV 16 E7 polypeptide, or a Bmil polypeptide.
- the set of IFs does not include a TERT polypeptide.
- the set of IFs does not include a SV40 Large T antigen.
- the set of IFS does not include a HPV 16 E6 polypeptide or a HPV 16 E7 polypeptide.
- the set of IFs includes three IFs, wherein two of the three IFs are an Oct3/4 polypeptide and a Sox2 polypeptide. In other cases, the set of IFs includes two IFs, wherein the two polypeptides are a c-Myc polypeptide and a Sox2 polypeptide. In some cases, the set of induction factors is limited to Oct 3/4, Sox2, and Klf4 polypeptides. In other cases, the set of induction factors may be limited to a set of four IFs: an Oct3/4 polypeptide, a Sox2 polypeptide, a Klf4 polypeptide, and a c-Myc polypeptide.
- a set of IFs may include IFs in addition to an Oct 3/4, a Sox2, and a Klf4 polypeptide.
- additional IFs include, but are not limited to Nanog, TERT, LIN28, CYP26A1, GDF3, FoxD3, Zfp42,
- the set of additional IFs does not include a c Myc polypeptide. In some cases, the set of additional IFs does not include polypeptides that might increase the risk of cell transformation.
- Forced expression of IFs may be maintained for a period of at least about 7 days to at least about 40 days, e.g., 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 25 days, 30 days, 33 days, or 37 days.
- the efficiency of inducing pluripotency in cells of a human population of cells is from at least about 0.001% to at least about 0.01% of the total number of cells to be induced, e.g., 0.002%, 0.0034%,
- Induction of the cells may be accomplished by combining histone deacetylase (HDAC) inhibitor treatment with forced expression of sets of IFs.
- HDAC histone deacetylase
- the cells to be induced may be undifferentiated stem cells present in a human postnatal tissue. In other cases, the cells to be induced are differentiated cells or are a mixture of differentiated or undifferentiated cells.
- the HDAC may be combined with the forced expression of a specific set of IFs, e.g., Oct 3/4, a Sox2, and a Klf4.
- a human somatic cell is induced to become pluripotent after HDAC inhibitor treatment is combined with forced expression of Oct3/4, Sox2 and Klf4 or forced expression of Oct3/4, Sox2, Klf4, and c-Myc.
- human pluripotent stem cells can be induced by introducing three genes of Oct3/4, Sox2 and Klf4 or three genes of Oct3/4, Sox2 and Klf4 plus the c-Myc gene or a HDAC inhibitor into undifferentiated stem cells present in a human postnatal tissue in which each gene of Tert, Nanog, Oct3/4 and Sox2 has not undergone epigenetic inactivation.
- human pluripotent stem cells are induced by introducing three genes of Oct3/4, Sox2 and Klf4 or three genes of Oct3/4, Sox2 and Klf4 plus the c-Myc gene or a histone deacetylase inhibitor into undifferentiated stem cells after the undifferentiated stem cells were amplified by a primary culture or a second subculture, or a subculture in a low density and subculturing in a culture medium comprising a low-concentration serum.
- Cells may be treated with one or more HDACs for about 2 hours to about 5 days, e.g., 3 hours, 6 hours, 12 hours, 14 hours, 18 hours, 1 day, 2 days, 3 days, or 4 days.
- Treatment with HDAC inhibitor may be initiated prior to beginning forced expression of IFs in the cells.
- HDAC inhibitor treatment begins during or after forced expression of IFs in the cells.
- HDAC inhibitor treatment begins prior to forced expression and is maintained during forced expression.
- Suitable concentrations of an HDAC inhibitor range from about 0.001 nM to about 10 mM, depending on the particular HDAC inhibitor to be used, but are selected so as to not significantly decrease cell survival in the treated cells.
- the HDAC concentration may range from 0.01 nM, to 1000 nM. In some embodiments, the HDAC concentration ranges from about 0.01 nM to about 1000 nM, e.g., about 0.05 nM, 0.1 nM, 0.5 nM, 0.75 nM, 1.0 nM, 1.5 nM, 10 nM, 20 nM, 40 nM, 50 nM, 100 nM, 200 nM, 300 nM, 500 nM, 600 nM, 700 nM, 800 nM, or other concentration from about 0.01 nM to about 1000 nM.
- Cells are exposed for 1 to 5 days or 1 to 3 days. For example, cells are exposed 1 day, 2 days, 3 days, 4 days or 5 days.
- HDAC inhibitor MS-275 is used.
- suitable HDAC inhibitors include, but are not limited to, any the following:
- Trichostatin A and its analogs for example: trichostatin A (TSA); and trichostatin C (Koghe et al. 1998, Biochem. Pharmacol. 56: 1359-1364).
- oxamflatin [(2E)-5-[3-[(phenylsulfonyl)aminophenyl]-pent-2-ene-4- inohydroxamic acid (Kim et al., Oncogene 18: 2461-2470 (1999)); Trapoxin A (cylco-(L-phenylalanyl- L-phenylalanyl-D-pipecolinyl-L-2-amino-8-oxo-9,10-epoxy-decanoyl) (Kijima et al., J. Biol. Chem.
- FR901228 depsipeptide
- FR225497 cyclic tetrapeptide
- apicidin cyclic tetrapeptide [cyclo-(N-O-metyl-L-tryptophanyl-L-isoleucinyl-D- pipecolinyl-L-2-amino-8-oxodecanoyl)] (Darkin-Rattray et al., Proc. Natl.
- HPC Hybrid polar compounds based on hydroxamic acid
- SBHA salicyl hydroxamic acid
- SAHA suberoylanilide hydroxamic acid
- SAHA suberoylanilide hydroxamic acid
- ABHA azelaic bishydroxamic acid
- AAHA azelaic- 1 -hydroxamate-9-anilide
- M-carboxy cinnamic acid bishydroxamide (CBHA) (Ricon et al., supra); 6-(3-chlorophenylureido) carpoic hydroxamic acid, 3-Cl-UCHA) (Richon et al., supra); MW2796 (Andrews et al., supra); and MW2996 (Andrews et al., supra).
- SCFA Short chain fatty acid
- valproic acid valerate (McBain et al., supra); 4-phenyl butyric acid (4-PBA) (Lea and Tulsyan, Anticancer RESearch 15: 879-3 (1995)); phenyl butyric acid (PB) (Wang et al., Cancer RESearch 59: 2766-99 (1999)); propinate (McBain et al., supra); butylamide (Lea and Tulsyan, supra); isobutylamide (Lea and Tulsyan, supra); phenyl acetate (Lea and Tulsyan, supra); 3-bromopropionate (Lea and Tulsyan, supra); tributyrin (Guan et al., Cancer RESearch 60: 749-55 (2000)); arginine butyrate; isobutyl amide; and valproate.
- 4-PBA 4-phenyl butyric acid
- PB phenyl butyric
- E. Benzamide derivatives for example: MS-275 [N-(2-aminophenyi)-4-[N-(pyridine-3-yl- methoxycarbonyl)aminomethyl]benzamide] (Saito et al., Proc. Natl. Acad. Sci. U.S.A. 96: 4592-7 (1999)); and a 3'-amino derivative of MS-275 (Saito et al., supra); and CI-994.
- a histone deacetylase inhibitor treatment may be carried out, for example, as follows.
- the concentration of the HDAC inhibitor may depend on a particular inhibitor, but is preferably 0.001 nM to about 10 mM, and more preferably about 0.01 nM to about 1000 nM.
- the effective amount or the dosage of a histone deacetylase inhibitor is defined as the amount of the histone deacetylase inhibitor that does not significantly decrease the survival rate of cells, specifically undifferentiated stem cells. Cells are exposed for 1 to 5 days or 1 to 3 days. The exposure period may be less than one day. In a specific embodiment, cells are cultured for about 1 to 5 days, and then exposed to an effective amount of a histone deacetylase inhibitor. However, the histone deacetylase inhibitor may be added at the start of culturing. Within such a time frame, a gene-carrying vehicle such as a vector containing a nucleic acid encoding three genes (Oct3/4, Sox2 and Klf4) is introduced into cultured cells by a known method.
- Forced expression of the IFs may comprise introducing one or more mammalian expression vectors encoding an Oct 3/4, a Sox2, and a Klf4 polypeptide to a population of cells.
- the IFs may be introduced into the cells as exogenous genes.
- the exogenous genes are integrated into the genome of a host cell and its progeny. In other cases, the exogenous genes persist in an episomal state in the host cell and its progeny.
- Exogenous genes are genes that are introduced to the cell from an external source.
- a gene as used herein is a nucleic acid that includes an open reading frame encoding a polypeptide of interest, e.g., an IF.
- the gene preferably includes a promoter operably linked to an open reading frame.
- a natural version of the gene may already exist in the cell but an additional "exogenous gene" is added to the cell to induce polypeptide expression.
- the one or more mammalian expression vectors may be introduced into greater than 20% of the total population of cells, e.g., 25%, 30%, 35%, 40%, 44%, 50%, 57%, 62%, 70%, 74%, 75%, 80%, 90%, or other percent of cells greater than 20%.
- a single mammalian expression vector may contain two or more of the just-mentioned IFs.
- one or more expression vectors encoding an Oct 3/4, Sox2, Klf4, and c Myc polypeptide are used.
- each of the IFs to be expressed is encoded on a separate mammalian expression vector.
- the IFs are genetically fused in frame with a transport protein amino acid sequence, e.g., that of a VP22 polypeptide as described in, e.g., U.S. Patent Nos. 6,521,455, 6,251,398, and 6,017,735.
- a transport protein amino acid sequence e.g., that of a VP22 polypeptide as described in, e.g., U.S. Patent Nos. 6,521,455, 6,251,398, and 6,017,735.
- Such VP22 sequences confer intercellular transport of VP22 fusion polypeptides from cells that have been transfected with a VP22 fusion polypeptide expression vector to neighboring cells that have not been transfected or transduced. See, e.g., Lemken et al (2007), MoI Ther, 15(2):310-319.
- IF-VP22 fusion polypeptides can significantly increase the functional efficiency of transfected mammalian expression vectors in the induction methods described herein.
- suitable mammalian expression vectors include, but are not limited to: recombinant viruses, nucleic acid vectors, such as plasmids, bacterial artificial chromosomes, yeast artificial chromosomes, human artificial chromosomes, cDNA, cRNA, and PCR product expression cassettes.
- Suitable promoters for driving expression of IFs in include retroviral LTR elements; constitutive promoters such as CMV, HSVl-TK, SV40, EF- l ⁇ , ⁇ actin; PGK, and inducible promoters, such as those containing Tet-operator elements.
- one or more of the mammalian expression vectors encodes, in addition to an IF, a marker gene that facilitates identification or selection of cells that have been transfected or infected.
- marker genes include, but are not limited to, fluorescent protein genes, e.g., for EGFP, DS-Red, YFP, and CFP; proteins conferring resistance to a selection agent, e.g., the neoR gene, and the blasticidin resistance gene.
- Forced expression of an IF may be accomplished by introducing a recombinant virus carrying DNA or RNA encoding an IF to one or more cells. Additionally, the recombinant virus may carry DNA or RNA encoding more than 1 IF. This includes multiple copies of a single IF or multiple IFs containined within a single virus. For ease of reference, at times a virus will be referred to herein by the IF it is encoding. For example, a virus encoding an Oct3/4 polypeptide, may be described as an "Oct3/4 virus.” In certain cases, a virus may encode more than one copy of an IF or may encode more than one IF, e.g., two IFs, at a time.
- the set of recombinant viruses may include combinations included in any set of IFs described herein.
- the set of recombinant viruses may include at least: an Oct3/4 virus, a Sox2 virus, and a Klf4 virus.
- the set of recombinant viruses may be limited to a set of four recombinant viruses: an Oct3/4 virus, a Sox2 virus, a Klf4 virus, and a c-Myc virus.
- the set of recombinant viruses is limited to a set of at least: an Oct3/4 virus, a Sox2 virus, a Klf4 virus, and a c-Myc virus.
- the set of recombinant viruses is limited to Oct 3/4, Sox2, and Klf4 viruses.
- the set of recombinant viruses may be limited a set of at least: an Oct3/4 virus, a Sox2 virus, and a Klf4 virus.
- the set of recombinant viruses includes three recombinant viruses, wherein two of the three recombinant viruses are an Oct3/4 virus and a Sox2 virus.
- the set of recombinant viruses may be limited to a Sox2 virus and a c- Myc virus.
- the set of recombinant viruses does not include a recombinant virus that encodes a polypeptide that might increase the risk of cell transformation, e.g., a c-Myc polypeptide.
- the set of recombinant viruses can include: an Oct3/4 virus, a Sox2 virus, and a Klf4 virus but not a c-Myc virus.
- the set of recombinant viruses includes a c-Myc virus.
- the c-Myc polypeptide encoded by the c-Myc virus may be wild-type c-Myc or a constitutive Iy active variant of c-Myc.
- the set includes a virus encoding c-Myc polypeptide capable of inducible activity, e.g., a c-
- Myc-ER polypeptide see, e.g., Littlewood, et al. (1995) Nucleic Acid Res. 23(10):1686-90.
- the set of recombinant viruses may include: an Oct3/4 virus, a Sox2 virus, and a Klf4 virus, but not a TERT virus, a SV40 Large T antigen virus, HPV 16 E6 virus, a HPV 16 E7 virus, or a Bmil virus.
- the set of recombinant viruses does not include a TERT virus.
- the set of recombinant viruses does not include a SV40 virus.
- the set of recombinant viruses does not include a HPV 16 E6 virus or a HPV 16 E7 virus.
- a set of recombinant viruses may include viruses in addition to an Oct 3/4, a Sox2, and a Klf4 virus.
- additional recombinant viruses include, but are not limited to Nanog, TERT, CYP26A1,
- thet set of recombinant viruses includes any IF variant descrbed herein.
- Individual viruses may be added to the cells sequentially in time or simultaneously.
- at least one virus e.g., an Oct3/4 virus, a Sox2 virus, a Klf4 virus, or a c-Myc virus, is added to the cells at a time different from the time when one or more other viruses are added.
- the virus e.g., an Oct3/4 virus, a Sox2 virus, a Klf4 virus, or a c-Myc virus
- Oct3/4 virus, Sox2 virus and K1F4 virus are added to the cells simultaneously, or very close in time, and the c-Myc virus is added at a time different from the time when the other viruses are added.
- At least two recombinant viruses may be added to the cells simultaneously or very close in time.
- Oct3/4 virus and Sox2 virus are added simultaneously, or very close in time, and the Klf4 virus or c-Myc virus is added at a different time.
- Oct3/4 virus and Sox2 virus; Oct3/4 virus and Klf4 virus; Oct3/4 virus and c-Myc virus; Sox2 virus and Klf4 virus; Sox2 virus and c-Myc virus; or Klf4 and c-Myc virus are added simultaneously or very close in time.
- At least three viruses e.g., an Oct3/4 virus, a Sox2 virus, and a Klf4 virus, are added to the cells simultaneously or very close in time.
- at least four viruses e.g.,
- Oct3/4 virus , Sox2 virus, Klf4 virus, and c-Myc virus are added to the cells simultaneously or very close in time.
- the efficiency of viral infection can be improved by repetitive treatment with the same virus.
- one or more Oct3/4 virus, Sox2 virus, Klf4 virus, or c-Myc virus is added to the cells at least two, at least three, or at least four separate times.
- recombinant viruses include, but are not limited, to retroviruses (including lentiviruses); adenoviruses; and adeno-associated viruses.
- retroviruses including lentiviruses
- adenoviruses adeno-associated viruses
- the recombinant retrovirus is murine moloney leukemia virus (MMLV), but other recombinant retroviruses may also be used, e.g., Avian
- Leukosis Virus Bovine Leukemia Virus, Murine Leukemia Virus (MLV), Mink-Cell focus-Inducing Virus, Murine Sarcoma Virus, Reticuloendotheliosis virus, Gibbon Abe Leukemia Virus, Mason Pfizer Monkey Virus, or Rous Sarcoma Virus, see, e.g., US Pat. No. 6,333,195.
- the recombinant retrovirus is a lentivirus (e.g., Human Immunodeficiency Virus- 1 (HIV-I); Simian Immunodeficiency Virus (SIV); or Feline Immunodeficiency Virus (FIV)), See, e.g., Johnston et al (1999), Journal of Virology 73(6)"4991-5000 (FIV); Negre D et al (2002) Current Topics in Microbiology and Immunology 261:53-74 (SIV); .Naldini et al (1996) Science.272:263-267 (HIV).
- HIV-I Human Immunodeficiency Virus- 1
- SIV Simian Immunodeficiency Virus
- FV Feline Immunodeficiency Virus
- the recombinant retrovirus may comprise a viral polypeptide (e.g., retroviral env) to aid entry into the target cell.
- a viral polypeptide e.g., retroviral env
- retroviral env e.g., retroviral env
- the viral polypeptide may be an amphotropic viral polypeptide, e.g., amphotropic env, that aids entry into cells derived from multiple species, including cells outside of the original host species. See, e.g., id.
- the viral polypeptide may be a xenotropic viral polypeptide that aids entry into cells outside of the original host species. See, e.g., id.
- the viral polypeptide is an ecotropic viral polypeptide, e.g., ecotropic env, that aids entry into cells of the original host species. See, e.g., id.
- examples of viral polypeptides capable of aiding entry of retroviruses into cells include but are not limited to: MMLV amphotropic env, MMLV ecotropic env, MMLV xenotropic env, vesicular stomatitis virus-g protein (VS V-g), HIV-I env, Gibbon Ape Leukemia Virus (GALV) env, RDl 14, FeLV-C, FeLV-B, MLV 10Al env gene, and variants thereof, including chimeras.
- ecotropic viral polypeptide e.g., ecotropic env
- examples of viral polypeptides capable of aiding entry of retroviruses into cells include but are not limited to: MMLV amphotropic env, MMLV ecotropic env
- the viral polypeptide is genetically modified to promote expression or enhanced binding to a receptor.
- a recombinant virus is produced by introducing a viral DNA or RNA construct into a producer cell. In some cases, the producer cell does not express exogenous genes.
- the producer cell is a "packaging cell" comprising one or more exogenous genes, e.g., genes encoding one or more gag, pol, or env polypeptides and/or one or more retroviral gag, pol, or env polypeptides.
- the retroviral packaging cell may comprise a gene encoding a viral polypeptide, e.g., VSV-g that aids entry into target cells.
- the packaging cell comprises genes encoding one or more lentiviral proteins, e.g., gag, pol, env, vpr, vpu, vpx, vif, tat, rev, or nef.
- the packaging cell comprises genes encoding adenovirus proteins such as ElA or ElB or other adenoviral proteins.
- proteins supplied by packaging cells may be retrovirus-derived proteins such as gag, pol, and env, lentivirus-derived proteins such as gag, pol, env, vpr, vpu, vpx, vif, tat, rev, and nef; and adenovirus- derived proteins such as ElA and ElB.
- the packaging cells supply proteins derived from a virus that differs from the virus from which the viral vector derives.
- Packaging cell lines include but are not limited to any easily-transfectable cell line.
- Packaging cell lines can be based on 293T cells, NIH3T3, COS or HeLa cell lines.
- As packaging cells any cells may be used that can supply a lacking protein of a recombinant virus vector plasmid deficient in at least one gene encoding a protein required for virus packaging.
- packaging cell lines include but are not limited to: Platinum-E (Plat-E); Platinum-A (Plat- A); BOSC 23 (ATCC CRL 11554); and Bing (ATCC CRL 11270), see, e.g., Morita et al (2000) Gene Therapy 7: 1063-1066; Onishi et al (1996) Experimental Hematology 24:324-329; U.S. Pat. No. 6, 995, 009.
- Commercial packaging lines are also useful, e.g., Ampho-Pak 293 cell line, Eco-Pak 2-293 cell line, RetroPack PT67 cell line, and Retro-X Universal Packaging System (all available from Clontech).
- the retroviral construct may be derived from a range of retroviruses, e.g., MMLV, HIV-I, SIV, FIV, or other retrovirus described herein.
- the retroviral construct may encode all viral polypeptides necessary for more than one cycle of replication of a specific virus. In some cases, the efficiency of viral entry is improved by the addition of other factors or other viral polypeptides. In other cases, the viral polypeptides encoded by the retroviral construct do not support more than one cycle of replication, e.g., U.S. Patent No. 6,872,528. In such circumstances, the addition of other factors or other viral polypeptides can help facilitate viral entry.
- the recombinant retrovirus is HIV- 1 virus comprising a VSV-g polypeptide but not comprising a HIV- 1 env polypeptide.
- the retroviral construct may comprise: a promoter, a multi-cloning site, and/or a resistance gene. Examples of promoters include but are not limited to CMV, SV40, EFl ⁇ , ⁇ actin; retroviral LTR promoters, and inducible promoters.
- the retroviral construct may also comprise a packaging signal (e.g., a packaging signal derived from the MFG vector; a psi packaging signal).
- retroviral constructs known in the art include but are not limited to: pMX, pBabeX or derivatives thereof. See e.g., Onishi et al (1996) Experimental Hematology 24:324-329.
- the retroviral construct is a self-inactivating lentiviral vector (SIN) vector, see, e.g., Miyoshi et al., (1998) J Virol. 72(10): 8150- 8157.
- the retroviral construct is LL-CG, LS-CG, CL-CG, CS-CG, CLG or MFG. Miyoshi et al., (1998) J Virol.
- Virus vector plasmids include: pMXs, pMXs-IB, pMXs-puro, pMXs-neo (pMXs-IB is a vector carrying the blasticidin-resistant gene in stead of the puromycin-resistant gene of pMXs-puro) [Experimental Hematology, 2003, 31 (11): 1007-14], MFG [Proc. Natl. Acad. Sci. U.S.A.
- the retroviral construct comprises blasticidin (e.g., pMXs-IB), puromycin (e.g., pMXs-puro, pBabePuro); or neomycin (e.g., pMXs-neo).
- blasticidin e.g., pMXs-IB
- puromycin e.g., pMXs-puro, pBabePuro
- neomycin e.g., pMXs-neo
- the retroviral construct may encode one or more IFs.
- pMX vectors encoding Oct3/4, Sox2, Klf4, or c-Myc polypeptides, or variants thereof are generated or obtained.
- Oct3/4 is inserted into pMXs-puro to create pMX-Oct3/4
- Sox2 is inserted into pMXs-neo to create pMX-Sox2
- Klf4 is inserted into pMXs-IB to create pMX-Klf4
- c-Myc is inserted into pMXs-IB to create pMX-c-Myc.
- pMX-Oct3/4, pMX-Sox2, pMX-Klf4 or pMX-c-Myc is introduced into PlatE cells by Fugene HD (Roche) transfection.
- the cell culture medium may be replaced with fresh medium comprising FBM (Lonza) supplemented with FGM-2 Single Quots (Lonza).
- the medium is replaced from about 12 to about 60 hours following the introduction of the viral construct, e.g., from about 12 to about 18 hours; about 18 to about 24; about 24 to about 30; about 30 to about 36; about 36 to about 42; about 42 to about 48; about 48 to about 54; or about 54 to about 60 hours following introduction of the viral construct to the producer cells.
- the medium may be replaced from about 24 to about 48 hours after introduction of the viral construct to the producer cells.
- the supernatant can be recovered from about 4 to about 24 hours following the addition of fresh media, e.g., about 4 hours. In some cases, the supernatant may be recovered about every 4 hours following the addition of fresh media.
- the recovered supernatant may be passed through a .45 uM filter (Millipore). In some cases, the recovered supernatant comprises retrovirus derived from one or more: pMX-Oct3/4, pMX-Sox2, pMX- Klf4 or pMX-c-Myc.
- Adenoviral transduction may be used to force expression of the sets of IFs.
- Methods for generating adenoviruses and their use are well established as described in, e.g., Straus, The Adenovirus, Plenum Press (NY 1984), 451 496; Rosenfeld, et al, Science, 252:431-434 (1991); U.S. Patent Nos. 6,203,975, 5,707,618, and 5,637,456.
- adenoviral-associated viral transduction is used to force expression of the sets of IFs.
- Methods for preparing adeno-associated viruses and their use are well established as described in, e.g., U.S. Patent Nos. 6,660,514 and 6,146,874.
- an adenoviral construct is obtained or generated, wherein the adenoviral construct, e.g., Adeno-X, comprises DNA encoding Oct3/4, Sox2, Klf4, or c-Myc.
- An adenoviral construct may be introduced by any method known in the art, e.g., Lipofectamine 2000 (Invitrogen) or Fugene HD (Roche), into HEK 293 cells.
- the method further comprises (1) collecting the cells when they exhibit a cytopathic effect (CPE), such effect occurring from about 10 to about 20 days, e.g., about 11, 13, 14, 15, 18, or 20 days after transfection (2) subjecting the cells to from about 2 to about 5 freeze -thaw cycles, e.g., about 3, (3) collecting the resulting virus-containing liquid; (4) purifying the virus using an adenovirus purification kit (Clontech) and (5) storing the virus at - 80 0 C.
- the titer, or plaque-forming unit (PFU), of the adenoviral stocks is determined using an Adeno-X rapid titer kit (Clontech), as described herein.
- the cells may be infected with a recombinant retrovirus that naturally targets a different cell type or cells originating from a different host.
- an exogenous receptor may be first introduced into the human cells.
- an exogenous mouse receptor may be added to human cells, e.g., postnatal dermal fibroblasts, in order help entry of murine moloney leukemia virus (MMLV).
- MMLV murine moloney leukemia virus
- the exogenous receptor may improve infection efficiency by facilitating viral entry, especially if the receptor recognizes a viral polypeptide, e.g., MMLV env, or HIV env.
- exogenous receptors include but are not limited to any receptor recognized by a specific retrovirus or lentivirus known in the art.
- a murine receptor mCATl, GenBank Accession No NM 007513 protein is used in order to aid MMLV infection of a human target cell.
- a CXCR4 or CCR5 receptor is used to aid HIV- 1 infection of a target cell.
- the exogenous receptor may be introduced by methods described herein. Methods of introducing the exogenous receptor include but are not limited to: calcium phosphate transfection, Lipofectamine transfection, Fugene transfection, microinjection, or electroporation.
- a virus e.g., recombinant adenovirus or retrovirus (including lentivirus), is used to introduce the exogenous receptor to the target cell.
- a recombinant adenovirus is used to introduce MCATl to human cells and then a recombinant retrovirus, e.g., MMLV, is used to introduce the IF genes, e.g., Oct 3/4, a Sox2, a Klf4, or c-Myc, to the cells.
- a solution of adenovirus comprising DNA encoding the mCATl protein, e.g., an adenovirus generated by using a pADEX-mCATl construct, is generated or obtained.
- the adenovirus solution can comprise Hanks' balanced salt solution.
- infection of cells is accomplished by: (1) contacting the p-ADEX-mCATl adenovirus solution with cells, e.g., human, non- embryonic fibroblasts, at a multiplicity of infection (m.o.i.) from about 1 :5 to about 1 :50, e.g., about 1 :5, about 1 :7; about 1 : 10; about 1 : 15, about 1 :20, about 1:25; about 1 :30, about 1 :35; about 1 :40; about 1 :45, or about 1 :50; (2) incubating the cells with the adenovirus solution at room temperature from about 15 minutes to about 2 hours, e.g., about 15 minutes, about 30 minutes, about 45 minutes, about 1 hour, about 1.25 hours, about 1.5 hours, about 1.75 hours, or about 2 hours; and (3) culturing the somatic cell population in culture medium from about 24 hours to about 60 hours, e.g., about 24 hours, about 30 hours, about
- the cells can be infected using a wide variety of methods.
- the infection of cells occurs by (1) combining one or more, two or more, three or more, or all four: pMX-Oct3/4 retrovirus, pMX-Sox2 retrovirus, pMX-Klf4, or pMX-c-Myc to obtain a retrovirus solution (2) supplementing the retrovirus solution with from about 2 ug/ml to about 15 ug/ml Polybrene, e.g., about 2 ug/ml, about 3 ug/ml, about 5 ug/ml, about 7 ug/ml, about 10 ug/ml, about 12 ug/ml, or about 15 ug/ml Polybrene; (3) contacting the retroviral solution with the somatic cells, at a m.o.i.
- step (3) e.g., about 1 :100, about 1 :150, about 1 :200, about 1 :250, about 1 :300, about 1 :350, about 1 :400, about 1 :450, or about 1 :500 m.o.i.; (4) allowing the contacting of step (3) to continue at 37° C from about 2 hours to about 24 hours, e.g., about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours; (5) soon after the contacting of step (4), changing the medium to MC-ES medium, as described herein; and (6) changing the MC-ES medium with fresh medium every 1 to 2 days.
- infection of somatic cells occurs by following steps (1) through (6) described herein, with the added step of pre-incubating the somatic cells for a length of time, e.g., about 48 hours, prior to contacting the cells with the retroviral solution.
- a length of time e.g., about 48 hours
- pre-incubation may be necessary when the somatic cell expresses an exogenous receptor that was introduced by viral transduction, transfection, or other method.
- an adenovirus or lentivirus is used to introduce an exogenous receptor, e.g., mCATl, to the somatic cell; such cells may need to be cultured for a length of time from at least about 30 hours to at least about 60 hours, e.g., about 30, about 35, about 40, about 48, about 52, about 55, or about 60 hours.
- the infection of cells may be accomplished by any method known in the art. e.g., Palsson, B., et al. WO95/10619. April 20, 1995; Morling, FJ. et al. (1995). Gene Therapy. 2: 504-508; Gopp et al. (2006) Methods Enzymol. 420:64-81.
- the infection may be accomplished by spin-infection or "spinoculation" methods that involve subjecting the cells to centrifugation during the period closely following the addition of virus to the cells.
- virus may be concentrated prior to the infection , e.g., by ultracentrifugation.
- other technologies may be used to aid or improve entry of retroviruses into the target cell.
- the retrovirus may be contacted with a liposome or immunoliposome to aid or direct entry into a specific cell type. See, e.g., Tan et al. (2007) MoI Med. 13(3-4): 216-226.
- the methods of infecting cells described herein may be used to infect cells expressing an exogenous receptor, e.g., MCATl or other exogenous receptor described herein. Depending on how the exogenous receptor was introduced, the preincubation period of the cells prior to infection may need to be varied. In some cases, cells that do not express an exogenous receptor are used. Some recombinant retroviruses, e.g., VSV-G pseudotyped recombinant retroviruses, may not need the aid of an exogenous receptor in order to efficiently enter cells. In some examples, VSV-G pseudotyped recombinant retrovirus is introduced to cells following the method described herein, except that the timing of the preculturing of the cells may vary.
- an exogenous receptor e.g., MCATl or other exogenous receptor described herein.
- Nucleic acid vector transfection e.g., transient transfection methods may be used to introduce
- Examples of high efficiency transfection efficiency methods include "nucleofection,” as described in, e.g., Trompeter (2003), J Immunol Methods, 274(l-2):245-256, and in international patent application publications WO2002086134, WO200200871, and WO2002086129, transfection with lipid-based transfection reagents such as Fugene® 6 and Fugene® HD(Roche), DOTAP, and lipofectamineTM LTX in combination with the PLUSTM (Invitrogen, Carlsbad, CA), DreamfectTM (OZ Biosciences, Marseille, France), GeneJuiceTM (Novagen, Madison, WI), polyethylenimine (see, e.g., Lungwitz et al (2005), Eur J Pharm Biopharm, 60(2):247-266), and Gene JammerTM (Stratagene, La Jo lla, CA), and nanoparticle transfection reagents as described in, e.g., U.S. Patent Application
- the induction methods may use protein transduction to introduce at least one of the IFs directly into cells.
- protein transduction method includes contacting cells with a composition containing a carrier agent and at least one purified polypeptide comprising the amino acid sequence of one of the above-mentioned IFs.
- suitable carrier agents and methods for their use include, but are not limited to, commercially available reagents such as ChariotTM (Active Motif, Inc., Carlsbad, CA) described in U.S. Patent No.
- the protein transduction method may comprise contacting a cells with at least one purified polypeptide comprising the amino acid sequence of one of the above-mentioned TAs fused to a protein transduction domain (PTD) sequence (IF-PTD fusion polypeptide).
- PTD protein transduction domain
- IF-PTD fusion polypeptide The PTD domain may be fused to the amino terminal of an IF sequence; or, the PTD domain may be fused to the carboxy terminal of an IF sequence.
- the IF-PTD fusion polypeptide is added to cells as a denatured polypeptide, which may facilitate its transport into cells where it is then renatured. Generation of PTD fusion proteins and methods for their use are established in the art as described in, e.g., U.S.
- Exemplary PTD domain amino acid sequences include, but are not limited to, any of the following: YGRKKRRQRRR (SEQ ID NO:1); RKKRRQRR (SEQ ID NO:2); YARAAARQ ARA (SEQ ID NO:3); THRLPRRRRRR (SEQ ID NO:4); and GGRRARRRRRR (SEQ ID NO:5).
- individual purified IF polypeptides are added to cells sequentially at different times.
- a set of at least three purified IF polypeptides, but not a purified c-Myc polypeptide, e.g., an Oct3/4 polypeptide, a Sox2 polypeptide, and a Klf4 polypeptide are added to cells.
- a set of four purified IF polypeptides, e.g., purified Oct3/4 , Sox2, Klf4, and c- Myc polypeptides are added to cells.
- the purified IF polypeptides are added to cells as one composition (i.e., a composition containing a mixture of the IF polypeptides).
- cells are incubated in the presence of a purified IF polypeptide for about 30 minutes to about 24 hours, e.g., 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 12 hours, 16 hours, 18 hours, 20 hours, or any other period from about 30 minutes to about 24 hours.
- protein transduction of cells is repeated with a frequency of about every day to about every 4 days, e.g., every 1.5 days, every 2 days, every 3 days, or any other frequency from about every day to about every four days
- Forced expression of IFs may also be achieved by using nucleic acid-free IF-containing protein transducing nanoparticles (PTN). Details of methods for generating and using PTNs are found in, e.g., Link et al (2006), Nuc Acids Res, 34(2) :e 16.
- the methods described herein utilize protein transduction and expression vector transduction/transfection in any combination to force expression of a set of IFs as described herein.
- retroviral expression vectors are used to force expression of Oct 3/4, a Sox2, and a Klf4 polypeptides in cells, and purified c-Myc purified polypeptide is introduced into cells by protein transduction as described herein.
- HDAC inhibitor treatment can be used in addition to the purified IF polypeptide.
- a set of at least three purified IF polypeptides, but not a purified c-Myc polypeptide, e.g., an Oct3/4 polypeptide, a Sox2 polypeptide, and a Klf4 polypeptide are added to cells which are also subjected to HDAC inhibitor treatment.
- Cell colonies may be subcloned by any method known in the art.
- the iPSCs are cultured and observed for about 14 days to about 40 days , e.g., 15, 16, 17, 18, 19, 20, 23, 24, 27, 28, 29, 30, 31, 33, 34, 35, 36, 37, 38 days, or any other period from about 14 days to about 40 days prior to identifying and selecting clones comprising "iPSCs" based on morphological characteristics.
- Morphological characteristics for identifying iPSC clones include, but are not limited to, a small cell size with a high nucleus-to-cytoplasm ratio; formation of small monolayer colonies within the space between parental cells (e.g., between fibroblasts).
- the cell suspension in the ring containing the detached colonies is then added to about 2 ml of MC ES medium (or other medium described herein), and plated in one well of a MEF-coated 24-well plate or other cell culture vessel of equivalent surface area. After culturing the colony-derived cells in a 5% CO 2 cell culture incubator at 37 0 C for about 14 hours, the medium is replaced. Subsequently, the medium is replaced about every two days until about 8 days later when a second subculture is carried out.
- MC ES medium or other medium described herein
- the medium in the first subculture, the medium is removed, the cells are washed with Hank's balanced salt solution, and Detachment Medium For Primate ES Cells (ReproCell, Tokyo, Japan) is then added to the cells and incubated at 37 0 C for 10 minutes. After the incubation, MC-ES medium (2 ml) is added to the resulting cell suspension to quench the activity of the Detachment Medium. The cell suspension is then transferred to a centrifuge tube, and centrifuged at 200 x g at 4 0 C for 5 minutes.
- Detachment Medium For Primate ES Cells (ReproCell, Tokyo, Japan) is then added to the cells and incubated at 37 0 C for 10 minutes. After the incubation, MC-ES medium (2 ml) is added to the resulting cell suspension to quench the activity of the Detachment Medium. The cell suspension is then transferred to a centrifuge tube, and centrifuged at 200 x g at 4 0 C for 5 minutes
- the supernatant is removed, the cell pellet is resuspended in MC ES medium, and the resuspended cells are plated on four wells of a MEF-coated 24-well plate and cultured for about seven days until a second subculture is prepared.
- the second subculture prepared by the method described above, cells are plated on a 60 mm cell culture culture dish coated with matrigel at a concentration of 20 ⁇ g/cm .
- a third subculture is prepared in which cells are plated on two matrigel-coated 60 mm cell culture dishes, one of which can subsequently be used for gene expression analysis and the other for continued passaging as described below.
- One of the subcultures is used for gene expression analysis, as described herein, and the other is passaged as needed to maintain a cell line derived from the iPSC clone.
- the iPSCs may be subcultured about every 5 to 7 days.
- the cells are washed with Hank's balanced salt solution, and dispase or Detachment Medium For Primate ES Cells is added, and incubated at 37 0 C for 5 to 10 minutes.
- MC-ES medium is added to quench enzymatic activity of the detachment medium, and the resulting cell/colony suspension is transferred to a centrifuge tube. Colonies in the suspension are allowed to settle on the bottom of the tube, the supernatant is carefully removed, and MC-ES medium is then added to resuspend the colonies.
- Examples of culture media useful for culturing human pluripotent stem cells induced from undifferentiated stem cells present in a human postnatal tissue of the present invention include, but are not limited to, the ES medium, and a culture medium suitable for culturing human ES cells such as MEF- conditioned ES medium (MC-ES) or other medium described herein, e.g.,. mTeSRTM. In some examples, the cells are maintained in the presence of a ROCK inhibitor, as described herein. IV. Analysis of Induced Cells
- Cell colonies subcultured from those initially identified on the basis of morphological characteristics may be assayed for any of a number of properties associated with pluripotent stem cells, including, but not limited to, expression of alkaline phosphatase activity, expression of ES cell marker genes, expression of protein markers, hypomethylation of Oct3/4 and Nanog promoters relative to a parental cells, long term self-renewal, normal diploid karyotype, and the ability to form a teratoma comprising ectodermal, mesodermal, and endodermal tissues.
- properties associated with pluripotent stem cells including, but not limited to, expression of alkaline phosphatase activity, expression of ES cell marker genes, expression of protein markers, hypomethylation of Oct3/4 and Nanog promoters relative to a parental cells, long term self-renewal, normal diploid karyotype, and the ability to form a teratoma comprising ectodermal, mesodermal, and endodermal tissues.
- a number of assays and reagents for detecting alkaline phosphatase activity in cells are known in the art.
- colonies to be analyzed are fixed with a 10% formalin neutral buffer solution at room temperature for about 5 minutes,e.g., for 2 to 5 minutes, and then washed with PBS.
- a chromogenic substrate of alkaline phosphatase, 1 step BCIP (5-Bromo-4-Chloro-3'-Indolyphosphate p-Toluidine Salt) and NBT (Nitro-Blue Tetrazolium Chloride) manufactured by Pierce (Rockford, IL) is then added and reacted at room temperature for 20 to 30 minutes. Cells having alkaline phosphatase activity are stained blue -violet.
- Putative iPS cell colonies tested for alkaline phosphatase activity may be then assayed for expression of a series of human embryonic stem cell marker (ESCM) genes including, but not limited to, Nanog, TDGFl, Dnmt3b, Zfp42, FoxD3, GDF3, CYP26A1, TERT, Oct 3/4, Sox2, SaIW, and HPRT.
- ECM embryonic stem cell marker
- levels of ESCM gene mRNA expression levels in putative iPS cell colonies are determined by qRT-PCR.
- Putative iPS cell colonies are harvested, and total RNA is extracted using the "Recoverall total nucleic acid isolation kit for formaldehyde- or paraformaldehyde- fixed, paraffin-embedded (FFPE) tissues" (manufactured by Ambion, Austin, TX).
- FFPE paraffin-embedded
- the colonies used for RNA extraction are fixed colonies, e.g., colonies that have been tested for alkaline phosphatase activity. The colonies can be used directly for RNA extraction, i.e., without prior fixation.
- the target gene is amplified using the TaqMan® PreAmp mastermix (manufactured by Applied Biosystems, Foster City, CA).
- Real-time quantitative PCR is performed using an ABI Prism 7900HT using the following PCR primer sets (from Applied Biosystems) for detecting mRNA of the above-mentioned ESCM genes: Nanog, Hs02387400_gl, Dnmt3b, Hs00171876_ml, FoxD3, Hs00255287_sl, Zfp42, HsO1938187_sl, TDGFl, Hs02339499_gl, TERT, Hs00162669_ml, GDF3, Hs00220998_ml, CYP26A1, Hs00175627_ml, GAPDH, Hs99999905_ml).
- Putative iPS cell colonies may be assayed by an immunocytochemistry method for expression of protein markers including, but not limited to, SSEA-3, SSEA-4, TRA- 1-60, TRA- 1-81, CD9, CD24, Thy-1, and Nanog.
- immunocytochemistry assays e.g., fluorescence immunocytochemistry assays, are known as described in, e.g., Harlow et al (1988), Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 353-355, and see also, The Handbook -A Guide to Fluorescent Probes and Labeling Technologies, Molecular Probes, Inc., Eugene, OR, (2004).
- expression of one or more of the above-mentioned protein markers in putative iPS cell colonies is assayed as follows. Cultured cells are fixed with 10% formaldehyde for 10 min and blocked with 0.1% gelatin/PBS at room temperature for about an hour. The cells are incubated overnight at 4°C with primary antibodies against SSEA-3 (MC-631; Chemicon), SSEA-4 (MC813-70; Chemicon), TRA-1-60 (abl6288; abeam), TRA- 1-81 (abl6289; abeam), CD9 (M- L13; R&D systems), CD24 (ALB9; abeam), Thyl (5E10; BD Bioscience), or Nanog (MAB1997; R&D Systems).
- Nanog staining cells are permeabilized with 0.1 % Triton X- 100/PBS before blocking. The cell colonies are washed with PBS three times, then incubated with AlexaFluor 488-conjugated secondary antibodies (Molecular Probes) and Hoechst 33258 (Nacalai) at room temperature for 1 h. After further washing, fluorescence is detected with a fluorescence microscope, e.g., Axiovert 200M microscope (Carl Zeiss).
- ESC marker genes in iPSC colonies may be assayed in live cells, which increases the efficiency of identifying iPSC colonies following an induction method as described herein.
- Examples of ESC marker genes useful for identifying induced stem cell colonies include, e.g., Oct3/4, Nanog, Klf4, Lin28, Sox2, c-Myc, or TERT.
- mRNA for one or more of these genes is detected in live cells.
- mRNAs for two or more of the ESC marker genes is detected.
- cells are contacted with one or more molecular beacon probes that hybridize to and signal the presence of one or more stem cell marker genes.
- Molecular beacons are single-stranded oligonucleotide hybridization probes that form a stem-and-loop structure.
- the loop contains a probe sequence that is complementary to a target sequence, and the stem is formed by the annealing of complementary arm sequences that are located on either side of the probe sequence.
- a fluorophore is covalently linked to the end of one arm and a quencher is covalently linked to the end of the other arm.
- MBs do not fluoresce when they are free in solution. However, when they hybridize to a target sequence they undergo a conformational change that enables them to fluoresce brightly.
- the probe sequence may range in length from about 15 to about 30 nucleotides depending on the GC content of the target probe sequence.
- the GC content of the target probe sequence should be from about 40 to about 60%.
- the flanking stem sequences may range from about 5 to about 7 nucleotides with a GC content of about 75 to about 100 percent.
- the design of MBs and their use to detect mRNA expression in living cells is known in the art, as described in, e.g., Rhee et al (2008), Nuc Acid Res, 36(5):e30.
- Useful algorithms for determining melting temperatures of an MB duplex and an MB/target duplex are known in the art.
- the iPSC colonies to be evaluated may be contacted about 14 days to about 50 days after initiating induction, e.g., 14 days to 21 days, 14 days to 28 days, 20 days to 45 days, 25 days to 40 days, 30 days to 35 days, 30 days to 50 days after induction.
- cells are contacted with as low a concentration of an MB and as short a period as compatible with reliably detecting a signal.
- the concentration of an MB of about 0.1 ⁇ M to about 5 ⁇ M (for each MB), e.g., 0.1 ⁇ M to 0.5 ⁇ M, 0.2 ⁇ M to 1 ⁇ M, 0.5 ⁇ M to 2 ⁇ M, or 3 ⁇ M to 5 ⁇ M.
- Incubation periods with a MB may range from about 5 minutes to about two hours, e.g., 15 minutes to 30 minutes, 20 minutes to one hour, 30 minutes to 1.5 hours, 45 minutes to 2 hours, or any other time period form about 5 minutes to two hours.
- MBs are introduced into the cells without the use of a transfection reagent.
- a transfection reagent optimized for oligonucleotide transfection is utilized, e.g., TransIT ® oligo transfection reagent kit or any other transfection reagents known in the art.
- streptolysin-0 is used to transiently permealize cells to allow entry of the MBs into the cells.
- MBs are added to adherent cell cultures and cell colonies found to be positive for expression of one or more ESC marker genes are picked off the substrate as described above.
- MBs are added to iPSCs in suspension and ESC-positive cells are selected by FACS or any other fluorescence based sorting method.
- MBs are added to adherent iPSCs, which are then dispersed prior to FACS selection. Use of FACS for selection of iPSCs is particularly useful for high throughput generation of iPSC lines and panels of iPSC lines.
- a characteristic of the iPSCs is reduced methylation of the genomic promoters of Oct3/4 and Nanog relative to those of their parental cells.
- Suitable Oct3/4 promoter regions to be analyzed include, but are not limited to, the Oct3/4 proximal promoter including conserved region 1 (CRl) and the Oct3/4 promoter distal enhancer including CR4.
- Suitable Nanog promoter regions to be analyzed include, but are not limited to, the Nanog proximal promoter including the Oct3/4 and Sox2 binding sites.
- genomic DNA isolated from putative iPSCs and cells used for a comparison is isolated and treated with bisulfite.
- Bisulf ⁇ te-treated genomic DNA is then PCR-amplified with primers containing a T7 promoter sequence.
- RNA transcripts are generated using T7 polymerase and then treated with RNAse A to generate methylation-specific cleavage products. Methylation of individual CpG sites is assessed by MALDI-TOF mass spectrometry of the cleavage products. A detailed description of the method is provided in, e.g., Ehich et al (2005), Proc Natl Acad Sci USA, 102: 15785- 15790.
- iPSCs are assessed for their ability to be passaged continuously in vitro. In some cases, the iPSCs are assayed for their ability to be passaged for at least about 30 to at least about 100 times in vitro, e.g., about 33, 35, 40, 45, 51, 56, 60, 68, 75, 80, 90, 93, 100, or any other number of passages from at least about 30 to at least about 100 passages.
- iPSCs are assayed for their ability to proliferate for a period of about 30 days to about 500 days from initiation of forced expression of IFs in parental cells, e.g., 40 days, 50 days, 60 days, 70 days, 80 days, 100 days, 150 days, 180 days, 200 days, 250 days, 300 days, 400 days, 450 days or any other period from about 30 days to about 500 days from initation of forced expression of IFs in the parental cells.
- long-term self-renewal of iPSCs is determined when the cells are passaged in a defined medium (e.g., mTeSRl medium) and in the absence of feeder cells, e.g., mTeSRl medium as described herein.
- a defined medium e.g., mTeSRl medium
- feeder cells e.g., mTeSRl medium as described herein.
- cells are passaged in MC-ES medium as described herein.
- iPSCs are assessed for diploidy and a normal, stable karyotype, e.g., stable after the cells of have been passaged for at least one year in vitro.
- a normal, stable karyotype e.g., stable after the cells of have been passaged for at least one year in vitro.
- a number of karotype analysis methods are known in the art.
- the karyotype analysis method is multicolor FISH as described in, e.g., Bayani et al (2004), Curr Protoc Cell Biol, Chapter 22:Unit 22.5.
- the karyotype analysis includes a molecular karyotype analysis as described in, e.g., Vermeesch et al (2007), Eur J Hum Genet, 15(11): 1105-1114.
- iPSCs are pretreated with 0.02 ⁇ g/ml colecemid for about 2 to about 3 hours, incubated with about 0.06 to about 0.075M KCl for about 20 minutes, and then fixed with Carnoy's fixative. Afterwards, for multicolor FISH analysis, cells are hybridized with multicolor FISH probes, e.g., those in the Star*FISH ⁇ Human Multicolour FISH (M-FISH) Kit from Cambio, Ltd (Cambridge, UK).
- M-FISH Human Multicolour FISH
- pluripotent stem cells have the ability to form a teratoma, comprising ectodermal, mesodermal, and endodermal tissues, when injected into an immunocompromised animal.
- Induced cells or induced pluripotent stem cells (iPS) or ES cell-like pluripotent stem cells may refer to cells having an in vitro long-term self-renewal ability and the pluripotency of differentiating into three germ layers, and said pluripotent stem cells may form a teratoma when transplanted into a test animal such as mouse.
- the iPSCs may be assessed for pluripotency in a teratoma formation assay in an immunocompromised animal model.
- the immunocompromised animal may be a rodent that is administered an immunosuppressive agent, e.g., cyclosporin or FK-506.
- the immunocompromised animal model may be a SCID mouse.
- About 0.5 x 10 6 to about 2.0 x 10 6 e.g., 0.6 x lO 6 , 0.8 x 10 6 , 1.0 x 10 6 , 1.2 x lO 6 , 1.5 x lO 6 , 1.7 x 10 6 , or other number of iPSCs from about 0.5 x 10 6 to about 2.0 x 10 6 iPSCs/mouse may be injected into the medulla of a testis of a 7-to 8-week-old immunocompromised animal. After about 6 to about 8 weeks, the teratomas are excised after perfusing the animal with PBS followed by 10% buffered formalin.
- the excised teratomas are then subjected to immunohistological analysis.
- One method of distinguishing human teratoma tissue from host (e.g., rodent) tissue includes immunostaining for the human-specific nuclear marker HuNu.
- Immunohistological analysis includes determining the presence of ectodermal (e.g., neuroectodermal), mesodermal, and endodermal tissues.
- Protein markers for ectodermal tissue include, but are not limited to, nestin, GFAP, and integrin Bl.
- Protein markers for mesodermal tissue include, but are not limited to, collagen II, Brachyury, and osteocalcin.
- Protein markers for endodermal tissue include, but are not limited to, ⁇ -fetoprotein ( ⁇ FP) and HNF3beta.
- global gene expression analysis is performed on putative iPS cell colonies.
- Such global gene expression analysis may include a comparison of gene expression profiles from a putative iPS cell colony with those of one or more cell types, including but not limited to, (i) parental cells, i.e., one or more cells from which the putative iPS cell colony was induced; (ii) a human ES cell line; or (iii) an established iPS cell line.
- parental cells i.e., one or more cells from which the putative iPS cell colony was induced
- a human ES cell line or
- gene expression data for human ES cell lines are available through public sources, e.g., on the world wide web in the NCBI "Gene Expression Omnibus" database.
- comparison of gene expression profiles from a putative iPS colony to those of an ES cell line entails comparison experimentally obtained data from a putative iPS cell colony with gene expression data available through public databases.
- human ES cell lines for which gene expression data are publicly available include, but are not limited to, hE14 (GEO data set accession numbers GSM151739 and GSM151741), Sheff4 (GEO Accession Nos GSM194307, GSM194308, and GSM193409), h_ES 01 (GEO Accession No. GSM194390), h_ES H9 (GEO Accession No. GSM194392), and h_ES BG03 (GEO Accession No. GSM194391).
- RNA isolated from one or more iPS cell lines by a nucleic acid microarray hybridization assay.
- suitable microarray platforms for global gene expression analysis include, but are not limited to, the Human Genome Ul 33 plus 2.0 microarray (Affymetrix) and the Whole Human Genome Oligo Micoarray (Agilent).
- gene expression data from cells produced by the methods described herein are compared to those obtained from other cell types including, but not limited to, human ES cell lines, parental cells, and multipotent stem cell lines.
- Suitable statistical analytical metrics and methods include, but are not limited to, the Pearson Correlation, Euclidean Distance, Hierarchical Clustering (See, e.g., Eisen et al (1998), Proc Natl Acad Sci USA, 95(25): 14863-14868), and Self Organizing Maps (See, e.g., Tamayo et al (1999), Proc Natl Acad Sci USA, 96(6):2907-2912.
- iPSC lines may be differentiated into cell-types of various lineages.
- differentiated cells include any differentiated cells from ectodermal (e.g., neurons and fibroblasts), mesodermal (e.g., cardiomyocytes), or endodermal (e.g., pancreatic cells) lineages.
- the differentiated cells may be one or more: pancreatic beta cells, neural stem cells, neurons (e.g., dopaminergic neurons), oligodendrocytes, oligodendrocyte progenitor cells, hepatocytes, hepatic stem cells, astrocytes, myocytes, hematopoietic cells, or cardiomyocytes.
- the differentiated cells derived from the iPSCs may be terminally differentiated cells, or they may be capable of giving rise to cells of a specific lineage.
- iPSCs can be differentiated into a variety of multipotent cell types, e.g., neural stem cells, cardiac stem cells, or hepatic stem cells.
- the stem cells may then be further differentiated into new cell types, e.g., neural stem cells may be differentiated into neurons; cardiac stem cells may be differentiated into cardiomyocytes; and hepatic stem cells may be differentiated into hepatocytes.
- Methods for differentiating iPSCs are further disclosed in U.S. application Nos.
- iPSCs There are numerous methods of differentiating the iPSCs into a more specialized cell type. Methods of differentiating iPSCs may be similar to those used to differentiate other stem cells, particularly ES cells, MSCs, MAPCs, MIAMI, hematopoietic stem cells (HSCs). In some cases, the differentiation occurs ex vivo; in some cases the differentiation occurs in vivo.
- Any known method of generating neural stem cells from ES cells may be used to generate neural stem cells from iPSCs, See, e.g., Reubinoff et al. (2001) Nat Biotechnol. 19(12): 1134-40.
- neural stem cells may be generated by culturing the iPSCs as floating aggregates in the presence of noggin, or other bone morphogenetic protein antagonist, see e.g., Itsykson et al. (2005) MoI Cell Neurosci. 30(l):24-36.
- neural stem cells may be generated by culturing the iPSCs in suspension to form aggregates in the presence of growth factors, e.g., FGF-2, Zhang et al. (2001), Nat.Biotech. (19) 1129 - 1133. In some cases, the aggregates are cultured in serum-free medium containing FGF-2.
- the iPSCs are co-cultured with a mouse stromal cell line, e.g., PA6 in the presence of serum-free medium comprising FGF-2.
- the iPSCs are directly transferred to serum- free medium containing FGF-2 to directly induce differentiation.
- Neural stems derived from the iPSCs may be differentiated into neurons, oligodendrocytes, or astrocytes. Dopaminergic neurons play a central role in Parkinson's Disease and are thus of particular interest.
- iPSCs may be co-cultured with a PA6 mouse stromal cell line under serum-free conditions, see, e.g., Kawasaki et al. (2000) Neuron 28(1):31-40.
- Other methods have also been described, see, e.g., Pomp et al. (2005), Stem Cells 23(7):923-30; U.S. Pat. No. 6,395,546.
- Oligodendrocytes may also be generated from the iPSCs.
- oligodendrocytes may be generated by co-culturing iPSCs or neural stem cells with stromal cells, e.g., Lee et al. (2000) Nature Biotechnol 18:675-679.
- oligodendrocytes may be generated by culturing the iPSCs or neural stem cells in the presence of a fusion protein, in which the Interleukin (IL)-6 receptor, or derivative, is linked to the IL-6 cyotkine, or derivative thereof.
- IL Interleukin
- Astrocytes may also be produced from the iPSCs. Astrocytes may be generated by culturing iPSCs or neural stem cells in the presence of neurogenic medium with bFGF and EGF, see e.g., Housele et al. (1999) Science 285:754-756.
- Induced cells may be differentiated into pancreatic beta cells by methods known in the art, e.g., Lumelsky et al. (2001) Science 292: 1389-1394; Assady et al., (2001) Diabetes 50: 1691-1697; D'Amour et al (2006) Nat Biotechnol:1392-1401 ' D'Amour et al. (2005) Nat Biotechnol 23: 1534-1541.
- the method may comprise culturing the iPSCs in serum-free medium supplemented with Activin A, followed by culturing in the presence of serum- free medium supplemented with all- trans retinoic acid, followed by culturing in the presence of serum- free medium supplemented with bFGF and nicotinamide, e.g., Jiang et al. (2007) Cell Res 4:333-444.
- the method comprises culturing the iPSCs in the presence of serum- free medium, activin A, and Wnt protein from about 0.5 to about 6 days, e.g., about 0.5, 1, 2, 3, 4, 5, 6, days; followed by culturing in the presence of from about 0.1% to about 2%, e.g., 0.2%, FBS and activin A from about 1 to about 4 days, e.g., about 1, 2, 3, 4 days; followed by culturing in the presence of 2% FBS, FGF- 10, and KAAD-cyclopamine (keto-N-aminoethylaminocaproyl dihydro cinnamoylcyclopamine and retinoic acid from about 1 to about 5 days, e.g., 1, 2, 3, 4, or 5 days; followed by culturing with 1% B27, gamma secretase inhibitor and extendin-4 from about 1 to about 4 days, e.g., 1, 2, 3, or 4 days; and finally culturing the
- Hepatic cells or hepatic stem cells may be differentiated from the iPSCs. For example, culturing the iPSCs in the presence of sodium butyrate may generate hepatocytes, see e.g., Rambhatla et al. (2003) Cell Transplant 12: 1-11. In another example, hepatocytes may be produced by culturing the iPSCs in serum- free medium in the presence of Activin A, followed by culturing the cells in fibroblast growth factor-4 and bone morphogenetic protein-2, e.g., Cai et al. (2007) Hepatology 45(5): 1229-39.
- the iPSCs are differentiated into hepatic cells or hepatic stem cells by culturing the iPSCs in the presence of Activin A from about 2 to about 6 days, e.g., about 2, about 3, about 4, about 5, or about 6 days, and then culturing the iPSCs in the presence of hepatocyte growth factor (HGF) for from about 5 days to about 10 days, e.g., about 5, about 6, about 7, about 8, about 9, or about 10 days.
- HGF hepatocyte growth factor
- the method may also comprise differentiating iPSCs into cardiac muscle cells.
- the method comprises culturing the iPSCs in the presence of noggin for from about two to about six days, e.g., about 2, about 3, about 4, about 5, or about 6 days, prior to allowing formation of an embryoid body, and culturing the embryoid body for from about 1 week to about 4 weeks, e.g., about 1, about 2, about 3, or about 4 weeks.
- cardiomyocytes may be generated by culturing the iPSCs may in the presence of LIF, or by subjecting them to other methods in the art to generate cardiomyocytes from ES cells, e.g., Bader et al. (2000) Circ Res 86:787-794, Kehat et al. (2001) J Clin Invest 108:407-414; ; Mummery et al. (2003) Circulation 107:2733-2740.
- Examples of methods to generate other cell-types from iPSCs include: (1) culturing iPSCs in the presence of retinoic acid, leukemia inhibitory factor (LIF), thyroid hormone (T3), and insulin in order to generate adipoctyes, e.g., Dani et al. (1997) J. Cell Sci 110: 1279-1285; (2) culturing iPSCs in the presence of BMP-2 or BMP-4 to generate chondrocytes, e.g., Kramer et al. (2000) Mech Dev 92: 193- 205; (3) culturing the iPSCs under conditions to generate smooth muscle, e.g., Yamashita et al.
- sub-populations of differentiated cells may be purified or isolated.
- one or more monoclonal antibodies specific to the desired cell type are incubated with the cell population and those bound cells are isolated.
- the desired subpopulation of cells expresses a reporter gene that is under the control of a cell type specific promoter.
- the hygromycin B phosphotransferase-EGFP fusion protein is expressed in a cell type specific manner.
- the method of purifying comprises sorting the cells to select green fluorescent cells and reiterating the sorting as necessary, in order to obtain a population of cells enriched for cells expressing the construct (e.g., hygromycin B phosphotransferase-EGFP) in a cell-type- dependent manner.
- Selection of desired sub-populations of cells may also be accomplished by negative selection of proliferating cells with the herpes simplex virus thymidine kinase/ganciclovir (HSVtk/GCV) suicide gene system or by positive selection of cells expressing a bicistronic reporter, e.g., Anderson et al. (2007) MoI Ther. (11):2027-2036.
- HSVtk/GCV herpes simplex virus thymidine kinase/ganciclovir
- the methods described herein utilize a panel of iPSC lines or a panel of cells differentiated from iPSC lines.
- a panel of iPSC lines comprises multiple iPSC lines, e.g., iPSC lines, that meet certain selection criteria.
- panels of cells differentiated from iPSC lines as described herein include, but are not limited to, panels of neural stem cells, neurons, retinal cells, glial progenitor cells, glial cells, cardiac progenitor cells, cardiomyocytes, pancreatic progenitor cells, pancreatic beta cells, hepatic stem cells, hepatocytes or lung progenitor cells.
- the selection criteria for inclusion of an iPSC line in a panel of iPSC lines are determined prior to generating the iPSC lines that will constitute the panel. In other cases, the selection criteria are applied to iPSC lines generated before hand, e.g., a bank of iPSC lines.
- Selection criteria include, but are not limited to, the presence or absence of a particular health condition in an iPSC donor, a positive drug response in an iPSC donor, negative, positive, or adverse drug responses in an iPSC donor, the presence or absence of a particular phenotype in an iPSC line or in cells differentiated from the iPSC line, and the presence or absence of one or more polymorphic alleles in the cell lines or their corresponding donors.
- the panel includes genetically diverse human iPSC lines in which each iPSC line carries at least one polymorphic allele that is unique among the iPSCs to be included in the panel, e.g., 5 to 10, 20 to 50, 50 to 200, 200 to 500, 500 to 1000, 1000 to 5000, 5000 to 20000, or 20000 to 50000 polymorphic alleles that are unique within the panel of iPSC lines.
- polymorphic alleles may include, e.g., a SNP allele, a promoter allele, or a protein-encoding allele.
- Polymorphic portions can be screened and scored for by genotyping using any of a number of known genotyping assays.
- the genotyping assay is a multiplexed genotyping assay, e.g., a nucleic acid microarray assay platform such as a "SNP chip.”
- the one or more polymorphic alleles are pre-selected.
- the one or more preselected alleles are polymorphic alleles associated with a health condition or a predisposition to a health condition.
- polymorphic alleles associated with a health condition or a predisposition to a health condition include, but are not limited to, polymorphic alleles associated with a neurodegenerative disorder, a neurological disorder, an eye disease, a mood disorder, a respiratory disease, a cardiovascular disease, an immunological disorder, a hematological disease, a metabolic disorder, or a drug sensitivity condition.
- polymorphic alleles associated with a health condition are provided in Table 3 above.
- Polymorphic alleles may include polymorphic alleles in an encoded protein or a regulatory sequence affecting the expression of the encoded protein. In some cases, the encoded protein is a drug target.
- the one or more polymorphic alleles are pre-selected based on the presence of a high degree of surrounding linkage disequilibrium in the genome, which has been proposed as a signature of genomic loci that are likely to impact many common health conditions. Methods for identifying SNPs having a high surrounding linkage disequilibrium and genes near such SNPs are described in, e.g., Wang et al (2006), Proc Natl Acad Sci USA, 103(l):135-140.
- a panel of iPSC lines includes iPSC lines generated from subjects that are diagnosed as suffering from one or more health conditions.
- the one or more health conditions may be one or more health conditions that are common to all of the iPSC donors, or they may be health conditions that are different between the iPSC donors.
- a panel of iPSC lines includes iPSC lines generated from subjects that are both diagnosed as suffering from a health condition and carry a polymorphic allele associated with a health condition, e.g., a polymorphic allele associated with the diagnosed health condition.
- a panel of iPSC lines may include iPSC lines from at least about 10 individuals to at least about 50,000 individuals, e.g., 10 to 50, 20 to 100, 50 to 250, 100 to 1000, 250, to 2000, 500 to 5000, 1000 to 10,000, 2500 to 20,000, 10,000,to 30,000, 20,000 to 40,000, or 30,000 to 50,000 individuals.
- a panel of iPSC lines may include iPSC lines from at least two ethnic groups, e.g., 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, or 50 ethnic groups.
- ethnic groups include, but are not limited to, Europeans, Japanese, Chinese, and the Yoruba of Nigeria, and ethnic groups listed in Table 4.
- iPSC lines and panels of iPSC lines described herein are useful in a number of methods relating to drug discovery and development.
- a drug candidate compound will be evaluated in a biochemical assay (e.g., a receptor binding assay) that evaluates only a single or very few sequence variants of the drug target expressed in a patient population.
- a biochemical assay e.g., a receptor binding assay
- assays provide little information as to how effective the drug candidate compound is likely to be in patients that express a drug target allele that differs from the particular drug target allele that was originally screened.
- drug candidate compounds often undergo functional cellular screens in one or few cell lines engineered to express a specific allele of the drug target, again ignoring the genetic diversity of a human patient population not only with respect to the drug target itself, but also to that of the various downstream signal transduction proteins that play a role in the response endpoint of cells to a drug.
- adverse effects of candidate drug compounds e.g., liver toxicity
- drug screening in panels of genetically diverse iPSC lines, as described herein addresses the lack of genetic diversity in the prevailing drug screening models.
- the panels of genetically diverse iPSC lines described herein may be used to identify test compounds that act on a drug target of interest.
- the panels of iPSCs cell lines include a sufficient number of iPSC lines such that at least two, e.g., at least 3, 5, 10, 20, 50, 100, or 200 polymorphic alleles of a drug target (e.g., a GPCR, ion channel, or kinase) are represented in the panel.
- panels of iPSC lines are derived from subjects diagnosed as suffering from a health condition or identified as having a predisposition to the health condition.
- the iPSC line panels comprise iPSC lines each of which that has at least one polymorphic allele associated with a health condition or a predisposition to the health condition.
- Drug targets for many health conditions are known.
- drug targets may include, but are not limited to, receptors, GPCRs, growth factor receptors, neurotransmitter receptors, ion channels, enzymes, protein kinases, proteases, cytoskeletal proteins, and transcription factors.
- Test compounds can be assayed for their effect on a drug target by a number of assays known in the art.
- assays include cell-based assays including, but not limited to, assays for determining second messenger levels, e.g., intracellular calcium, cAMP, cGMP, arachidonic acid, and inositol phosphates; channel currents; apoptosis; proliferation; morphological changes; changes in adhesion.
- Cell based assays may also include determining the cellular localization of one or more proteins (e.g., protein kinases, receptors, and transcription factors) in cells in the presence or absence of a test compound. Test compounds may also be screened for their ability to alter a gene expression profile by any gene expression profiling method known in the art. In some cases, the cells to be screened may be genetically modified to express one or more reporter proteins that can indicate activation of a signaling pathway. For example protein-protein interactions between fusion proteins introduced into cells may be detected by a number of methods known in the art, e.g., by fluorescence resonance energy transfer (FRET) or enzyme fragment complementation.
- FRET fluorescence resonance energy transfer
- the mechanistic basis of a sporadic form of a disease is a combination of genetically-determined cell type-specific phenotype and epigenetic factors (e.g., oxidative stress).
- epigenetic factors e.g., oxidative stress.
- iPSC-derived differentiated cells from a patient with a sporadic form of a disease may bear a genetic predisposition to a pathological or pre -pathological cellular phenotype (e.g., apoptosis), but the phenotype may only manifest in vitro in the presence of an appropriate "stressor" that recapitulates environmental/epigenetic factors associated with the sporadic disease or a cellular phenotypes that precede a clinical manifestation of the disease (e.g., mitochondrial dysfunction, oxdidative stress, or nitrosylative stress).
- disease-relevant cellular phenotypes are induced by a stressor.
- stressors include, but are not limited to cellular oxidative stress, nitrosylative stress, proteasome inhibition, inhibition of mitochondrial electron transport, translation inhibition, decreased calcium buffering, high osmolality, heat shock, heavy metals (e.g., Zn, Mn, Fe, Cd, Al, or Pb), protein misfolding.
- agents that induce, increase, or result from oxidative stress include, but are not limited to, H 2 O 2 , ascorbic acid/FeSO/t, 4-hydroxynonenal, glutamate, kainate, NMDA, dopamine, okadaic acid, A ⁇ 1"42 and isocyanate.
- Proteasome inhibitors include, but are not limited to lactacystin, ziram, MG 132, and carbobenzoxy-L-isoleucyl-gamma-t-butyl-L-glutamyl-L- alanyl-L-leucinal (PSI).
- Mitochondrial stressors include, but are not limited to, rotenone, 3- nitropropionic acid (NPA), 1 -methyl-4-phenylpyridinium (MPP + ) , antimycin, paraquat, methylglycoxal, and cyanide.
- Nitrosylative stressors include, but are not limited to, (+/-)-S-nitroso-N- acetylpenicillamine, sodium nitroprussiate, and peroxynitrite.
- the stressor is provided by expressing or overexpressing an exogenous wild type or mutated gene and/or protein.
- genes include, ⁇ -synuclein, amyloid beta, A ⁇ 1"42 , Parkin, Pinkl, Leucine-rich repeat kinase 2 (LRRK2), superoxide dismutase (SOD).
- Assays of drug candidate compounds in an iPSC line or a panel of iPSC lines can include determining a dose-response.
- the dose response of an iPSC line or that of one or more types of cells differentiated from the iPSC line provides an indication that of the likely efficacy of the compound in the corresponding iPSC donor.
- the fraction of iPSC lines in a panel of iPSC lines that exhibit an acceptable dose-response to a test compound indicates an expected probability of an acceptable dose-response relationship in the target patient population of interest.
- cell-based assays of drug candidate include a comparison of responses obtained in a panel of iPSC lines or iPSC-derived cells to one or more reference iPSC lines or cells that serve as a positive or negative control for the effect of a drug candidate compound.
- the reference iPSC lines or cells may be from a healthy iPSC donor, from an iPSC donor diagnosed as suffering from a health condition, or an iPSC donor carrying a polymorphic allele associated with a health condition.
- assays of drug candidate compounds in an iPSC line or a panel of iPSC lines can include determining effective concentrations, maximum tolerated dose and minimum effective concentration. Additional methods and assays are disclosed in US application No. 61/061,594, WSGR Docket Number 36588- 707.101; filed 6/13/08; First Inventor Kazuhiro Sakurada, hereby incorporated by reference. [00202] In some cases, the drug screening may be conducted on cells differentiated from iPSCs.
- differentiated cells examples include hepatic cells, neural stem cells, neurons, pancreatic beta cells, cardiomyocytes, hepatic stem cells, oligodendrocytes.
- the drugs may be targeted to treat a specific disease or condition, e.g., a disease or condition described herein.
- the iPSCs may be differentiated into dopaminergic neurons, which are used to screen drugs for Parkinson's disease.
- neurons or neural stem cells differentiated from iPSCs may be used to screen drugs for treating Alzheimer's disease, multiple sclerosis, or other neurological disorders.
- the iPSCs may be transplanted directly into an immunocompromised animal, e.g., SCID mouse, which is then used to establish in vitro or in vivo assay systems that mimic physiologic conditions in humans or other animals.
- the in vitro or in vivo assay systems may be used to screen for drugs, e.g., drugs for Parkinson's disease, or as a means to identify biological mechanisms.
- Screening of test compounds may also be conducted in iPSC-derived cells when an abnormal cellular phenotype (e.g., abnormal cell morphology, gene expression, or signaling), associated with a health condition or a predisposition to the health condition is known, but a drug target has not yet been identified.
- an abnormal cellular phenotype e.g., abnormal cell morphology, gene expression, or signaling
- Such assays may include contacting a test population of iPSC-derived cells from one or more iPSC donors with a test compound and contacting with a negative control compound a negative control population of iPSC-derived cells from the same one or more iPSC donors.
- the assayed cellular phenotype associated with the health condition of interest in the test and negative control populations can then be compared to a normal cellular phenotype. Where the assayed cellular phenotype in the test population is determined as being closer to a normal cellular phenotype than that exhibited by the negative control population, the drug candidate compound is identified as normalizing the phenotype.
- a normal cellular phenotype with respect to a particular health condition or a predisposition for a health condition may be established in iPSC-derived cells from iPSC donors that do not suffer from the health condition or a predisposition for the health condition.
- Test compounds identified as lead compounds may be tested on a panel of iPSC-derived cells in a manner analogous to a clinical trial.
- the efficacy of the lead compound versus a negative control compound, e.g., a placebo compound is determined in a panel of iPSC-derived cells from patients suffering from the same health condition.
- a panel of iPSC-derived cells is from subjects that are genetically diverse.
- such patients may be carry at least one polymorphic allele that is unique among the iPSC-derived cells to be included in the panel, e.g., 5 to 10, 20 to 50, 50 to 200, 200 to 500, 500 to 1000, 1000 to 5000, 5000 to 20000, or 20000 to 50000 polymorphic alleles that are unique within the panel of iPSC lines.
- a number of methods for quantifying the genetic diversity of a population are known in the art, e.g., the analysis of molecular variance (AMOVA) and generalized analysis of molecular variance (GAMOVA).
- the efficacy of the lead compound in iPSC-derived cells may be determined based on any cellular response endpoint, e.g., a response obtained in any of the cell-based assays or gene expression profiling assays mentioned herein.
- Drug candidate compounds may be individual small molecules of choice (e.g., a lead compound from a previous drug screen) or in some cases, the drug candidate compounds to be screened come from a combinatorial library, i.e., a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical "building blocks.”
- a combinatorial library such as a polypeptide library is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound).
- Combinatorial chemical libraries include, but are not limited to: diversomers such as hydantoins, benzodiazepines, and dipeptides, as described in, e.g., Hobbs et al. (1993), Proc. Natl. Acad. ScL U.S.A.
- combinatorial libraries are commercially available from, e.g., ComGenex (Princeton, NJ); Asinex (Moscow, Russia); Tripos, Inc. (St. Louis, MO); ChemStar, Ltd. (Moscow, Russia); 3D Pharmaceuticals (Exton, PA); and Martek Biosciences (Columbia, MD).
- iPSC cell lines and iPSC-derived cells generated from a subject can be used to determine the likelihood that a particular drug will have sufficient efficacy in that subject and, if so, an appropriate dose range for that subject.
- a subject e.g., a human subject
- iPSC- derived cells from a subject e.g., differentiated iPSC-derived cells may be exposed ex vivo to a drug to be tested, and then assayed for their phenotypic response to the drug as described herein.
- the response of the iPSC-derived cells may be compared to a reference response obtained in iPSC-derived cells from one or more individuals in which the drug has been shown to be effective and/or a reference response in iPSC-derived cells from subjects in which the drug was found to be ineffective.
- the subject to be tested is a subject suffering from a health condition or a predisposition to the health condition. For example, where the subject is suffering from a health condition, and multiple drugs are available to treat the health condition, the efficacies and adverse effects of the multiple drugs may be evaluated iPSC-derived cells from that individual.
- the iPSC-derived cells used to test drug efficacy include cells that express at least one drug target (e.g., a neurotransmitter receptor).
- the subject is not suffering from a health condition.
- drugs for various health conditions are tested preemptively in iPSC-derived cells from a healthy subject to establish a pharmaco- phenomic profile for that subject. The pharmaco-phenomic profile may subsequently be used as needed for selecting optimal drugs and drug dosing for treatment of the particular subject.
- Candidate therapeutic agents are those that normalize a disease-associated cellular phenotype, i.e., alter the relevant cellular phenotype in the patient- derived cells so that it is closer to the corresponding cellular phenotype in cells derived from normal subjects under the same conditions.
- the therapeutic agent may alter a cellular phenotype of ⁇ patient-derived iPSCs so as to protect them from a stressor, as described herein.
- Sets of data representing various cellular phenotypes (e.g., mitochondrial ROS production, expression profiles, protein aggregation) in patient iPSC-derived cells versus normal subject iPSC- derived cells constitute vectors in a multidimensional space, amenable to analysis by means of multivariate and univariate statistical and machine learning techniques.
- cellular phenotypes distinguishing patient versus normal subject can be identified, for example, by means of univariate statistical methods, such as t-test, ANOVA, regression, as well as their non-parametric analogs.
- cellular phenotype data are further filtered using various statistical criteria, e.g., p-value of significance (Typel error), effect size, etc.
- cellular phenotypes which differ significantly between disease and normal states are further scrutinized by biological pathways analysis.
- a pathway enrichment analysis is performed to further narrow the set of cellular phenotypes which are the most disease-informative.
- a number of statistical procedures such as Hypergeometric statistic, Kolmogorov-Smirnoff test, etc, can be used to perform pathway enrichment analysis.
- cellular phenotypes that are found to differ significantly in patient versus normal subjects i.e., disease-relevant cellular phenotypes
- disease-relevant cellular phenotypes are confirmed by performing validation/cross-validation analysis on the independent data sets from the same type of cellular phenotype assays.
- disease-relevant cellular phenotypes are determined by first assaying and analyzing only a portion of the available patient and normal iPSC lines, and then validating disease- relevant cellular phenotypes in the remaining iPSC lines.
- other statistical approaches such as k-fold cross-validation techniques, are used instead.
- one or more validated cellular phenotypes is then used to assess test agents for their ability to convert one or more cellular phenotypes reflecting a disease condition to cellular phenotypes reflecting a normal condition.
- a "wellderly" subject refers to any subject that is at least 80 years old and has not suffered from any major chronic diseases. Selection of wellderly individuals as normal control subjects makes it statistically less likely that such individuals will go on to develop a degenerative condition. Thus, iPSCs derived from such individuals are less likely to exhibit a cellular phenotype that is associated or predictive of the disease being analyzed, and therefore provide a more reliable "normal control" phenotype for purposes of comparison to patient-derived iPSCs and iPSC-derived cells. In other embodiments, elderly individuals are selected for control iPSC generation that while not having suffered from a degenerative disease under study, may have suffered other unrelated degenerative diseases. In other cases, age-matched subjects free of the disease to be analyzed are used to generate normal control subject iPSCs.
- efficacy is tested in larger panels of patient iPSC-derived cells to identify potential variation in efficacy or toxicity of the candidate therapeutic agent.
- efficacy is tested in iPSCs or iPSC-derived cells from at least about 20 to about 500 patients, e.g., at least about 25, 30, 40, 50, 60, 70, 100, 200, 250, 300, 400, or another number of patients from at least about 20 to about 500 patients.
- biomarkers associated with responsiveness to a candidate therapeutic agent or lack of responsiveness to a candidate therapeutic agent are identified and used to stratify a patient population into, e.g., "high responders” (HR) and “low responders” (LR), as schematized in Fig. 4.
- HR high responders
- LR low responders
- biomarkers are used to identify suitable patients for clinical trials of a candidate therapeutic agent.
- biomarkers are used to predict the responsiveness or potential toxicity of a therapeutic agent for particular patients.
- biomarkers include genomic biomarkers (e.g., SNPs, a CNVs, or other genetic polymorphisms).
- the biomarkers include an expression profile signature (e.g., an mRNA expression profile).
- the biomarkers may include a protein expression profile or even a single protein expression level. In some cases, where the biomarkers are expression profile biomarkers, these may be determined directly from a patient sample (e.g., blood, urine, sputum, hair, skin, or other biological sample taken directly from the patient). In other embodiments, expression profile biomarkers, are specific to patient iPSCs or iPSC-derived cells in which the candidate therapeutic agent or therapeutic agent is tested.
- iPSCs are derived from patients and control subjects, and the iPSCs are differentiated into disease-relevant cell types thereby allowing a comparison of cellular phenotypes in patient-derived cells versus normal subject derived cells.
- the cellular phenotype that is compared may include a mitochondrial phenotype, e.g., ATP synthesis, ATP/ADP ratio, mitochondrial potential, calcium buffering, production of reactive oxygen species, mitochondrial fusion and fission, mitochondrial morphology, and mitochondrial movement.
- the cellular phenotype that is compared is the fraction and rate at which a particular cell type is undergoing apoptosis in the presence of a stressor.
- the cellular phenotype is protein aggregation (e.g., the formation of lewy bodies).
- gene expression e.g., microRNA expression is compared between patient- derived cells and normal subjects.
- relational databases are constructed that integrate multiple data streams relating to each patient and control iPSC line.
- data include, but are not limited to, one or more of the following: patient medical history and family medical history, patient medical data (e.g., blood pressure, liver enzyme levels), patient adverse drug reactions, patient drug responsiveness, partial or complete genomic sequence, sequence of all genes with known disease-associated alleles, comprehensive SNP genotypes (e.g., genotypes for all SNPs with known disease associations), gene copy number variation (CNV) polymorphisms, expression profiles for iPSCs and for cells differentiated from the iPSCs (e.g., dopaminergic neurons, cortical neurons, motor neurons, pancreatic cells, hepatocytes, cardiomyocytes, and vascular epithelial cells) under resting and under various stimulus paradigms (e.g., in the presence of a stressor), all cellular phenotype assay data used for initial pathway discovery and for drug screening, including, e.g.,
- a user can query such a database based on any set of criteria with user define limits. For example, a user may wish to identify polymorphisms associated with patients whose iPSC-derived dopaminergic neurons did or did not respond to a candidate therapeutic agent. In another example, a user may wish to identify a common gene expression profile that distinguishes motor neurons that showed a severe apoptotic response to a stressor versus a mild apoptotic response, etc. Such databases are very useful for data mining and establishing robustly predictive signatures for specific disease states and their response to candidate therapeutic agents.
- SMA Spinal Muscular Atrophy
- the disease exhibits a wide range of severity affecting infants through adults, and is subdivided into types I-IV based on the age of onset and severity of symptoms: Type I "Infantile” onset at ages 0-6 months and generally fatal); Type II “Intermediate,” onset at ages 7-15 months; inability to stand or walk, but some ability to maintain a sitting position; Type III “Juvenile” onset at ages 18 months to 17 years, with some ability to walk, though potentially transient; Type IV "Adult,” some muscle weakness, but no genetic basis is known.
- SMA Survival Motor Neuron
- the region of chromosome 5 that contains the SMN (survival motor neuron) gene has a large duplication.
- a large sequence that contains several genes occurs twice — i.e. once in each of the adjacent segments.
- the two copies of the gene known as SMNl and SMN2 — differ by only a few base pairs.
- the SMN2 gene contains a mutation that occurs at the splice junction of intron 6 to exon 7 resulting in about 90% of SMN2 pre-mRNA transcripts being spliced into a form that excludes exon 7.
- This shorter mRNA transcript codes for a truncated SMN protein, which is rapidly degraded. About 10% of pre-mRNA transcript from SMN2 is spliced into the full length transcript that codes for the fully functional SMN protein. This splicing defect occurs in multiple cell types, although, for unknown reasons, the survival of motor neurons appear to be particularly affected.
- SMA results from the loss of the SMNl gene from both chromosomes, and its severity, ranging from SMA 1 to SMA 3, largely depends on whether the level of SMN2 E7 transcript can make up for low levels or absence of exon 7-inclusive SMN 1 transcript.
- the mutations that cause the loss of SMN 1 are of two types. Deletion mutations, in which both copies of the SMNl are missing. The other type of mutation is a conversion mutation in which both copies of the SMNl gene have a point mutation resulting in the same splicing pattern as the SMN2 gene.
- SMN2 E7 exon 7-inclusive SMN2 transcript
- Induction of iPSCs was initiated by transduction of SMNl 7" and SMNl 7+ fibroblast cultures with four MoMLV VSV-G-pseudotyped viruses for expression of human OCT4, SOX2, KLF4, and c- MYC, each at an MOI of about 10.
- fibroblasts were switched from human fibroblast medium into human ES cell supportive medium and monitored daily for the appearance of putative iPSC colonies based on morphological criteria.
- SM8c iPSC line was shown to differentiate into mature motor neurons as shown by double immunolabeling for Islet and Neuro-N (data not shown).
- Example 2 Assay for Identification of Molecules that Improve Molecular and Cellular Disease Phenotvpes in Motor Neurons from Patients Suffering from Spinal Muscular Atrophy
- increased levels of SMN2 E7 transcript can be increased by boosting SMN2 transcription, reducing degradation of SMN2 mRNA, or by increasing the fraction of SMN2 pre-mRNA that is spliced into SMN2 E7 mRNA.
- SMA patient-specific motor neurons are obtained by first generating panels of iPS cell lines from Type I, Type II, and Type III SMA patients, as described in Example 1, and subsequently differentiating iPSCs into motor neurons. Prior to motor neuron differentiation SMA patient SMN2 minigene reporter iPSC lines are established to provide a convenient readout for the level of SMN2 E7 transcript in motor neurons.
- iPSC line database For each SMA-iPSC line to be generated, the following corresponding patient information is collected and annotated in an iPSC line database: disease severity ranking (i.e., Type I, II, or III), age of disease onset, patient medical history, family medical history including incidence of ALS, blood level of SMN protein, SMNl and SMN2 genotypes, MUNE Motor Unit Number Estimation, Hammersmith SMA Functional Motor Scale ranking, breathing test evaluation (only for children >5yrs), symptom progression evaluation (e.g., how outcome of motor tests has changed over time), muscle mass index, description of therapeutic interventions to date, and therapy response.
- disease severity ranking i.e., Type I, II, or III
- age of disease onset i.e., patient medical history, family medical history including incidence of ALS, blood level of SMN protein, SMNl and SMN2 genotypes
- MUNE Motor Unit Number Estimation Hammersmith SMA Functional Motor Scale ranking
- breathing test evaluation only for
- Biopsy samples are stored for up to 5-7 days at 4 0 C in a "biopsy medium" containing KO- DMEM and supplemented with 10% fetal bovine serum (FBS), Earl's Salts, nucleosides, beta- mercaptoethanol (BME), non-essential amino acids, glutamine, and penicillin/streptomycin.
- FBS fetal bovine serum
- BME beta- mercaptoethanol
- Biopsies are minced into 4-5 pieces, and the pieces are then transferred to a 60 mm dish. The pieces are then "sandwiched” under an acid-washed coverslip and cultured in biopsy medium for five days. Subsequently, the sandwiched biopsy explants are cultured in human fibroblast ("hFib") medium containing KO-DMEM, Earl's Salts, 10% FBS, glutamine, penicillin/streptomycin, and medium is replaced every 3-4 days until the coverslip is confluent. SMA iPSCs are generated, as described in Example 1 , from fibroblasts obtained from each biopsy.
- hFib human fibroblast
- An SMN2 splicing minigene reporter construct is generated that incorporates exons 6, 7, and 8, and utilizing the SMN2 promoter is generated essentially as described in Zhang et al (2001), Gene Ther., 8: 1532-1538 and Wilson et al, Stem Cells and Development, 16: 1027-1041.
- the SMN2 reporter construct will incorporate the DD-AmCyanl fluorescent protein reporter to maximize the signal to noise ratio in a compound screening reporter gene assay.
- the DD-AmCyanl protein contains a degradation ("DD") domain that conditionally destabilizes the protein thereby keeping "background" levels of the reporter protein prior to a test compound screening assay very low.
- the reporter protein upon addition of the cell- permeable "Shieldl” ligand (Invitrogen), which selectively binds to the DD domain, the reporter protein is stabilized and can therefore accumulate.
- DD-AmCyanl reporter levels in the presence or absence of test compounds are maximized by measuring almost exclusively reporter protein produced after the beginning of the screening assay, i.e., after the addition of the Shieldl ligand and test compound.
- Additional reporter constructs will include AmCyanl or luciferase as the reporter.
- Other constructs will include the CMV promoter to drive SMN2 minigene expression.
- the SMN2 reporter construct is then stably transfected into type I, type II, and type III SMA-iPSCs and healthy control (SMNl w ⁇ /w ⁇ ) iPSCs to generate SMN2-reporter SMA-iPSC lines of varying disease severity backgrounds, and SMN2 reporter control iPSC lines, respectively.
- Primary screening of test compounds for the ability to increase properly spliced SMN2 transcript levels is conducted initially in motor neurons derived from Type I SMA reporter iPSCs.
- EBs are washed, gently resuspended in EB medium, and replated in a new ULA 6-well plate, and the wash/replate procedure is repeated on day 8 or 9.
- EBs are collected and resuspended in N2 base medium (DMEM/F12, Glutamax (Invitrogen, catalog# 10565), N-2 Supplement (Invitrogen, catalog# 17502-048), D-Glucose (Sigma, catalog# G8769), Ascorbic Acid (Sigma, catalog# A4403-100mG)) supplemented with 1 ⁇ M Retinoic Acid (RA) and 100 nM Purmorphamine. (PM).
- N2 base medium DMEM/F12, Glutamax (Invitrogen, catalog# 10565), N-2 Supplement (Invitrogen, catalog# 17502-048), D-Glucose (Sigma, catalog# G8769), Ascorbic Acid (Sigma, catalog# A4403-100mG)
- RA Retin
- EBs are transferred to in N2 Base medium+ 1 ⁇ M RA + 1 ⁇ M Purmorphamine and replated (3 ml of EB suspension/well) on ULA 6 well plates.
- N2 base [00228] The RA (1 ⁇ M)/PM (1 ⁇ M)-supplemented EB medium is replaced every 3-5 days, as needed, until approximately day 28. Afterwards, EBs are dissociated by dilute papain treatment and gentle trituration, and then replated on new ULF 6-well plates followed by gentle trituration every 10 minutes over a period of 45 minutes.
- the resulting cell suspension is collected and transferred to a 50 ml conical tube containing motor neuron maturation medium (DMEM/F12, Glutamax, N-2 Supplement (Invitrogen, catalog# 17502-048), B-27 Supplement (Invitrogen, catalog# 17504-044), D- Glucose, Ascorbic Acid (Sigma, catalog# A4403-100mG), 2ng/mL each GDNF (R&D, catalog# 212- GD), BDNF (R&D, catalog# 248-BD), and CNTF (R&D, catalog# 257-NT/CF).
- motor neuron maturation medium DMEM/F12, Glutamax, N-2 Supplement (Invitrogen, catalog# 17502-048), B-27 Supplement (Invitrogen, catalog# 17504-044), D- Glucose, Ascorbic Acid (Sigma, catalog# A4403-100mG), 2ng/mL each GDNF (R&D, catalog# 212- GD), BD
- the cell suspension is pelleted by centrifugation at 1000 RPM for five minutes, and is then resuspended in motor neuron maturation medium at a cell concentration of approximately 1.6 x 10 6 cells/ml. Aliquots (50 ⁇ l) of cell suspension are then plated on laminin-coated wells of optical grade 96 well plates. Beginning on day 31 , half-medium changes are conducted every other day or every day depending on how quickly the medium becomes spent. The differentiated cultures are maintained in motor neuron differentiation medium for another four weeks prior to beginning SMN2-reporter assays to allow expansion and maturation of the motor neuron population.
- SMN2 reporter levels Compounds that increase SMN2 reporter levels (“candidate therapeutic” compounds) are screened in secondary assays for their ability to increase SMN2 E7 transcript levels and for their ability to promote SMA motor neuron survival over a period of about two weeks. Candidate therapeutic compounds are then tested on motor neurons derived from additional type I SMA SMN2-reporter iPSC lines, and from type II and type III iPSC lines to validate the effect of the therapeutic candidate compounds on motor neurons from diverse genetic backgrounds extant in the SMA patient population.
- Parkinson's Disease is one of the most common neurodegenerative diseases of aging, affecting 1-2% of the population over 65 years of age. Clinical symptoms include rest tremor, bradykinesia, and rigidity. We seek to generate a PD patient iPSC model to identify candidate therapeutic agents that slow, halt, or reverse PD progression.
- iPSC lines are generated from skin biopsies obtained from 10 healthy control subjects with no known family history of PD, 10 patients with sporadic PD, patients each with mutations in the genes that encode ⁇ -synuclein (PARKl), parkin (PARK2), PINK 1 (PARK6), or LRRK2 (PARK8) for a total of 10 patients for each mutation.
- iPSCs are generated as described in Example 1. Afterwards, dopaminergic neurons are derived by differentiating each of the patient iPSC lines and control subject iPSCs.
- a dopaminergic phenotype is established by immunocytochemical staining for tyrosine hydroxylase positivity, and assaying the differentiated cells for the ability to synthesize and release dopamine.
- Dopaminergic neurons are obtained by differentiating the iPSCs according to the method of Perrier et al (2004), Proc Natl Acad Sci U S A 101, 12543-12548. After validating the dopaminergic phenotype of neurons differentiated from each of the above iPSC lines, cultures of the patient iPSC-derived dopaminergic neurons are tested in a battery of cellular phenotype assays and compared to control subject dopaminergic neurons.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6159408P | 2008-06-13 | 2008-06-13 | |
US6159208P | 2008-06-13 | 2008-06-13 | |
PCT/US2009/047291 WO2009152484A2 (en) | 2008-06-13 | 2009-06-12 | Methods and platforms for drug discovery |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2297332A2 true EP2297332A2 (de) | 2011-03-23 |
EP2297332A4 EP2297332A4 (de) | 2012-03-21 |
Family
ID=41417418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09763772A Withdrawn EP2297332A4 (de) | 2008-06-13 | 2009-06-12 | Verfahren und plattformen zur arzneistoffentdeckung |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2297332A4 (de) |
CN (1) | CN102203275A (de) |
WO (2) | WO2009152484A2 (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120171771A1 (en) * | 2009-07-08 | 2012-07-05 | Cellular Dynamics International, Inc. | Modified ips cells having a mutant form of a human immunodeficiency virus (hiv) cellular entry gene |
WO2011119942A1 (en) * | 2010-03-25 | 2011-09-29 | Vistagen Therapeutics, Inc. | Induction of ips cells using transient episomal vectors |
EP2563907B1 (de) | 2010-04-28 | 2019-06-19 | The J. David Gladstone Institutes | Verfahren zur erzeugung von kardiomyozyten |
US9228204B2 (en) | 2011-02-14 | 2016-01-05 | University Of Utah Research Foundation | Constructs for making induced pluripotent stem cells |
WO2012116111A1 (en) * | 2011-02-22 | 2012-08-30 | Sanford-Burnham Medical Research Institute | METHOD AND COMPOUNDS FOR GENERATION OF iPSCs |
WO2013033213A1 (en) | 2011-08-30 | 2013-03-07 | The J. David Gladstone Institutes | Methods for generating cardiomyocytes |
JP2018537118A (ja) * | 2015-10-05 | 2018-12-20 | オリジェン, インコーポレイテッド | 肝機能不全の同定および緩和に基づくパーキンソン病の診断および処置 |
CN107603951B (zh) * | 2016-07-12 | 2020-08-14 | 中国人民解放军军事医学科学院基础医学研究所 | 一种用于在体诱导成熟神经元分裂的新型生长/神经营养因子组合物及其用途 |
GB2583309A (en) * | 2017-12-28 | 2020-10-21 | Ibm | Neuron model generation for personalised drug treatment |
US11227692B2 (en) * | 2017-12-28 | 2022-01-18 | International Business Machines Corporation | Neuron model simulation |
CN109294975A (zh) * | 2018-10-23 | 2019-02-01 | 山东华思生物科技有限公司 | 一种干细胞药物筛选方法 |
US20220028488A1 (en) * | 2018-12-07 | 2022-01-27 | President And Fellows Of Harvard College | Drug discovery and early disease identification platform using electronic health records, genetics and stem cells |
WO2020129366A1 (ja) * | 2018-12-21 | 2020-06-25 | アイ ピース, インコーポレイテッド | 健康リスク情報管理装置、健康リスク情報管理方法、およびプログラム |
CN111621546A (zh) * | 2020-06-18 | 2020-09-04 | 上海诚益生物科技有限公司 | 一种利用原代肝细胞筛选甲状腺素受体激动剂的方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060222636A1 (en) * | 2003-09-19 | 2006-10-05 | The Rockefeller University | Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells |
WO2009061442A1 (en) * | 2007-11-06 | 2009-05-14 | Children's Medical Center Corporation | Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999010536A1 (en) * | 1997-08-22 | 1999-03-04 | Yale University | A process to study changes in gene expression in granulocytic cells |
US20040048297A1 (en) * | 2002-07-30 | 2004-03-11 | Gene Logic, Inc. | Nucleic acid detection assay control genes |
WO2005095583A1 (en) * | 2004-03-03 | 2005-10-13 | Life-Sciences Ag | Large scale storage of viable somatic stem and/or progenitor cells |
WO2005097190A2 (en) * | 2004-03-26 | 2005-10-20 | Celgene Corporation | Systems and methods for providing a stem cell bank |
US20090074731A1 (en) * | 2007-09-13 | 2009-03-19 | Librach Clifford L | Method of isolation and use of cells derived from first trimester umbilical cord tissue |
-
2009
- 2009-06-12 EP EP09763772A patent/EP2297332A4/de not_active Withdrawn
- 2009-06-12 CN CN2009801275028A patent/CN102203275A/zh active Pending
- 2009-06-12 WO PCT/US2009/047291 patent/WO2009152484A2/en active Application Filing
- 2009-06-12 WO PCT/US2009/047293 patent/WO2009152485A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060222636A1 (en) * | 2003-09-19 | 2006-10-05 | The Rockefeller University | Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells |
WO2009061442A1 (en) * | 2007-11-06 | 2009-05-14 | Children's Medical Center Corporation | Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells |
Non-Patent Citations (3)
Title |
---|
EBERT ALLISON D ET AL: "Induced pluripotent stem cells from a spinal muscular atrophy patient", NATURE 15 JAN 2009,, vol. 457, no. 7227, 15 January 2009 (2009-01-15), pages 277-280, XP002552498, DOI: 10.1038/NATURE07677 * |
MALI PRASHANT ET AL: "Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts", STEM CELLS (MIAMISBURG), vol. 26, no. 8, 29 May 2008 (2008-05-29), pages 1998-2005, XP002668773, ISSN: 1066-5099 * |
See also references of WO2009152484A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009152485A3 (en) | 2010-05-14 |
CN102203275A (zh) | 2011-09-28 |
WO2009152484A2 (en) | 2009-12-17 |
WO2009152485A2 (en) | 2009-12-17 |
WO2009152484A3 (en) | 2010-03-11 |
EP2297332A4 (de) | 2012-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8257941B2 (en) | Methods and platforms for drug discovery using induced pluripotent stem cells | |
EP2297332A2 (de) | Verfahren und plattformen zur arzneistoffentdeckung | |
US20120122212A1 (en) | Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells | |
Zimmerlin et al. | Tankyrase inhibition promotes a stable human naïve pluripotent state with improved functionality | |
Boulting et al. | A functionally characterized test set of human induced pluripotent stem cells | |
Almeida et al. | Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects | |
JP6774333B2 (ja) | 年齢改変細胞および年齢改変細胞を作製するための方法 | |
Okata et al. | Embryonic type Na+ channel β-subunit, SCN3B masks the disease phenotype of Brugada syndrome | |
Lépine et al. | Homozygous ALS-linked mutations in TARDBP/TDP-43 lead to progressive synaptic dysfunction in human iPSC-derived motor neurons | |
US9523674B2 (en) | Method of screening for substances capable of promoting induction of induced pluripotent stem cells | |
Chung et al. | Investigation of the functional impact of CHED-and FECD4-associated SLC4A11 mutations in human corneal endothelial cells | |
van den Hurk | Neuronal identity and maturation: insights from the single-cell transcriptome | |
Shimamoto | Generation and Characterization of Induced Pluripotent Stem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110111 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: KYOTO UNIVERSITY |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20120221 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/15 20060101ALI20120213BHEP Ipc: C12Q 1/02 20060101AFI20120213BHEP |
|
17Q | First examination report despatched |
Effective date: 20130424 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140924 |